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1. Introduction 
The mechanisms of defense systems in plants are very complex. 
The diversification and evolution of secondary metabolites such 
as pyrrolizidine alkaloids (PAs) constitutes a clear example of the 
confrontation between plants and microorganisms/insects.1 PAs 
are currently of special interest because several of them have 
been shown to cause toxic, genotoxic and carcinogenic reactions 
in humans when ingested with foods or herbal medicines.2,3 
Natural PAs are frequently hydroxylated, O-alkylated or O-
acylated at key positions of the bicyclic heterocycle. Thus, for 
instance, the most common skeletal formula of retronecine (1: 
R1, R2 = H) has a hydroxyl group at the C1 whilst the 
hydroxymethyl group is bonded to the C7. On the other hand, 
some natural PAs bearing two hydroxy groups at 1- and 2-
positions and a hydroxymethyl group at 7-position, such as (+)-
crotanecine (2), madurensine (3) and anacrotine (4), isolated 
from crotalaria species, have been widely used for the treatment 
of bacterial and viral infections as well as for cancer.4 A rare 
class of pyrrolizidines such as (+)-amphorogynines A (5) and D 
(6), characterized by substitution at C-2 by an hydroxyl group 
and a carboxylic group at C-7 were isolated from Amphorogynine 
spicata were also identified,5 as well as the polyhydroxylated 
casuarine (7),6 which was extracted from Casuarina equisitefolia 
(Figure 1). Non-hydroxylated natural pyrrolizidines shown in 
Figure 2 also exhibit potent glycosidase inhibition apart from 
other biological properties.2 
The synthesis of all these alkaloids is not so simple, for 
example, (+)-2 and (+)-5, have been prepared by 
diastereoselective [4+2] cycloadditions using nitroalkenes and a 
chiral vinyl ether,4a,b and by diastereoselective [2+2] 
dichloroketene-chiral enol ether cycloaddition,6 respectively. 
Besides, (–)-8 to (–)-10 scaffolds were prepared by double 
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A general synthesis of highly substituted pyrrolizidines can be performed by a multicomponent 
1,3-dipolar cycloaddition using proline ester hydrochlorides, aldehydes and dipolarophiles, at 
room temperature without catalysts or in the presence of AgOAc (5 mol%). In the case of 
(2S,4R)-4-hydroxyproline derivatives it is possible to obtain enantioenriched pyrrolizidines with 
high control of the regio- and diastereoselectivity affording the adducts 2,4-trans-2,5-trans
according to an endo-approach and a S-dipole geometry of the in situ generated azomethine 
ylide. For proline esters a similar regioselectivity and endo-diastereoselectivity are observed 
when the dipole promotes an α-attack. However, when ethyl glyoxylate is used as aldehyde 
component the γ-attack of the S-ylide takes place preferentially giving rise the opposite 
regioselectivity for acrylic dipolarophiles, being crucial the role of silver acetate. In this case, the 
exo-adducts with a 2,3-cis-2,5-trans relative configuration are diastereoselectively obtained. In 
addition, computational studies have also been carried out to shed light on the origins of the 
diastereo- and regioselectivity observed for the described 1,3-dipolar cycloadditions. 
2015 Elsevier Ltd. All rights reserved.
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reductive amination7 or through a biomimetic Mannich-type 
reaction,8 or by metathesis.9 
In order to facilitate their synthesis, several diastereoselective 
approaches to these heterocyclic frameworks have been 
successfully attempted. For instance, chain elongations of proline 
derivatives followed by cyclization,10  transanular 
iodoamination11 using lactams,12 from other natural products,13 
etc. However, the most important and straightforward route is to 
employ a 1,3-dipolar cycloaddition (1,3-DC)14,15,16 using mainly 
nitrones17,18,19,20 or azomethine ylides.21,22,23,24,25,26,27,28 
 
Figure 1. C6 or C2-hydroxylated pyrrolizidines. 
 
 
Figure 2. Non-hydroxylated pyrrolizidine alkaloids.  
Felluga et al. described a three component decarboxylative 1,3-
DC using proline 11a or (2S,4R)-4-hydroxyproline 11b and 2,3-
butanedione or ethyl pyruvate with β-nitrostyrene to give, at 
room temperature, a mixture of diastereomeric pyrrolidines 12 in 
good yields (78-90%) (Scheme 1).25 More recently, it has been 
found that proline 11a itself underwent a domino iminium salt 
formation with α,β-unsaturated β-keto esters followed by 
decarboxylation and diastereoselective cycloaddition with the 
named keto ester at 80 ºC in DMSO as solvent, to give regio- and 
diastereoselectively 13 in good chemical yields (80-90%) 
(Scheme 1).25 
 
 
Scheme 1. Pyrrolizidine synthesis from azomethine ylides generated by 
decarboxylation of prolines.25,26 
According to all these features, azomethine ylides derived from 
enantiomerically enriched commercially available (2S,4R)-4-
hydroxyproline 14,26 or its t-butyldimethylsilyl derivative 15,26 
synthetic enantiomerically enriched polysubstituted proline 
surrogate 16, or even proline 1726,27 or 4-thiaproline 18 methyl 
ester hydrochlorides, and aldehydes were envisaged to undergo 
diastereoselective cycloadditions with electrophilic alkenes 
providing the pyrrolizidine nucleus. In this work the scope of the 
synthesis of non-natural pyrrolizidine alkaloids I or II employing 
this multicomponent diastereoselective 1,3-DC of azomethine 
ylides, prepared in situ following a non-decarboxylative iminium 
route by reaction of 14-18 with aldehydes will be described 
(Scheme 2). We will also take in consideration several 
computational studies for the clarification and rationalization of 
the high diastereoselection observed in the most representative 
transformations. 
 
 
Scheme 2. Retrosynthetic analysis of pyrrolizidines prepared in this work 
by multicomponent 1,3-DC. 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3 
2. Results and Discussion 
2.1. Multicomponent 1,3-DC with enantiomerically enriched 
(2S,4R)-4-hydroxyproline methyl ester hydrochloride 14, with 
its derivative 15, and cycloadduct 16 
When the multicomponent 1,3-DC involving (2S,4R)-4-
hydroxyproline methyl ester hydrochloride 14 was performed 
employing cinnamaldehyde, as iminium precursor, and methyl 
acrylate as dipolarophile, in toluene with 1 equiv. of 
triethylamine at room temperature, the reaction took place in 4 h 
obtaining 85% yield of a 80:20 mixture of compounds endo-19a 
and endo-19a’ (Scheme 3). These reaction conditions were 
initially settled due to the previous experience gained from other 
multicomponent 1,3-cycloadditions published by our group.27,29,30 
The employment of other different solvents such as DCM, or 
THF at room temperature gave lower diastereoselection. The 
introduction of a bulkier protecting group at the hydroxy 
functionality was carried out onto molecule 14 to give 15 with 
the aim to study the diastereoselection of the corresponding 
reaction product endo-19b,31 but the final diastereomeric ratio of 
endo-19b:endo-19b’ was slightly lower  (78:18 dr, Scheme 3). 
In light of the absolute configuration of the major 2,4-trans-
2,5-cis-diastereoisomers 19, which were unambiguously 
established after X-ray diffraction analysis of endo-19a,27 it can 
be deduced that a preferential α-attack of the less sterically 
hindered S-shape dipole A occurred (Figure 3).The approach of 
the acrylate took place in an endo-manner and by the same face 
where the hydroxy group is located (Scheme 3). Comparative 
nOe, and bidimensional experiments and analysis of the 
corresponding coupling constants confirmed the proposed 
structure also for the minor pyrrolizidines 19’, in this case the 
acrylate reacting by the opposite face to give 19a’ with a 2,4-
trans-2,5-trans-relative configuration. The observed 2,5-trans 
arrangement is in agreement with a S-shape dipole A, which is 
more stable than the U-shape one A (Figure 3).32 This last 
intermediate would afford the 2,5-cis relative configuration. The 
stereochemical results are very different to those observed for the 
1,3-DC of acyclic dipoles generated from imino esters, which 
gave, through a W-shape conformation 2,5-cis substituted endo-
prolines III (Figure 4).33 Chemical shifts in 1H NMR and 
coupling constants are very similar between 19 and 19’ but there 
is a very important nOe HC5→CO2Me bonded to the quaternary 
centre in both molecules. 
 
 
Scheme 3. Multicomponent 1,3-DC of cinnamaldehyde and methyl 
acrylate with (2S,4R)-4-hydroxyproline methyl ester hydrochlorides 14 and 
its TBDMS surrogate 15. 
 
 
 
Figure 3. Intermediate 1,3-dipoles A derived from (2S,4R)-4-
hydroxyproline methyl ester 14 and 15. 
 
 
 
Figure 4. Prolines derived from a 1,3-DC of acyclic imino esters. 
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The study of the general scope and the increment of the 
diastereoselection moved us to test several acrylic derivatives 
maintaining the aldehyde structure. Thus, the incorporation of 
tert-butyl acrylate instead of methyl acrylate produced an 
increment of the diastereoselection (90:10 dr) of the product 
endo-19c (Scheme 4), which was isolated in 80% yield after flash 
chromatography. Besides, the dr could be improved to a 98:2 
when the reaction was catalyzed with silver acetate (5 mol%) and 
the corresponding product 19c was isolated (82% yield) in 
enantiomerically pure form.  
(E)-3-(But-2-enoyl)oxazolidin-2-one was also tested as 
dipolarophile and the diastereoselection was even higher 
obtaining up to 95:5 dr for endo-19d independently of the 
method A or B employed (Scheme 4). Thus, cycloadducts endo-
19c and endo-19d can be isolated as optically pure enantiomers. 
In these two examples the endo-selectivity was almost complete 
and the regiochemistry of the process followed the same pattern 
discussed previously for the reaction involving alkyl acrylates. 
The assignment of the absolute configuration of the major 
compounds endo-19c and endo-19d was done by analogy to 
compound 19a because its CHN signal in 1H NMR is slowly 
shifted (0.1-0.2 ppm) at lower fields than the identical signal of 
the compound 19a’.   
 
 
 
Scheme 4. Multicomponent 1,3-DC between (2S,4R)-4-hydroxyproline 
methyl ester hydrochloride 14, cinnamaldehyde and α,β-unsaturated 
compounds. 
 
 
 
 
In contrast, N-methylmaleimide gave a lower 
diastereoselection when using (2S,4R)-4-hydroxyproline methyl 
ester hydrochloride 14 as starting material. In this reaction 
pyrrolizidines endo-19e and endo-19e’ were isolated in 80-81% 
yield and 75:25 dr by using both A and B methods (Scheme 5). 
The presence of both diastereoisomers can be explained by the 
corresponding α-attack of the S-shape dipole A by both faces 
(Figure 3). The interest of these fused tricyclic pyrrolizidines 
containing the maleimide residue was demonstrated in a series of 
publications dealing with analogous skeletons inhibitors of 
thrombin.34  
Again, the structure of  major compounds endo-19e versus 
endo-19e’ was was confirmed by the lower field shift of CHN 
signal in 1H NMR. 
 
 
 
Scheme 5. Multicomponent 1,3-DC between (2S,4R)-4-hydroxyproline 
methyl ester hydrochloride 14, cinnamaldehyde and NMM. 
 
With respect to the effect of Lewis acids such as Ti(OPri)4, 
ZnCl2, and AgOAc in the diastereoselection of the overall 
process either activating the dipolarophile or forming the silver 
enolate in the dipole was investigated. Only AgOAc was able to 
promote the reaction generating very clean reaction products 
endo-19. To understand the effect of the silver salt, a parallel 
study was undertaken. In all transformations the results of the 
cycloadditions run in the presence of silver acetate were 
compared with the analogous reactions performed without it. As 
it was mentioned (above), an improvement of the diastereomeric 
ratio was observed in the reaction where tert-butyl acrylate was 
the selected dipolarophile. In this example, compound 19c was 
isolated in good chemical yield (82%) and 98:2 dr (Scheme 4). 
Reactions involving N-alkenoyl oxazolidinone and NMM did not 
reveal any variation of diastereoselection when working in the 
presence of 5 mol% of silver acetate (Scheme 4 and 5). In both 
silver-catalyzed and non-catalyzed processes the crude reaction 
mixtures of diastereoisomers were very clean (1H NMR 
spectroscopy) and isolated yields were excellent as it was shown 
in Schemes 4 and 5. 
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When benzaldehyde, instead of cinnamaldehyde, was 
allowed to react with (2S,4R)-hydroxyproline methyl ester 
hydrochloride 14 and tert-butyl acrylate endo-20a (>99:1 dr) as 
unique product was obtained in 75% yield (Scheme 6). 
Polysubstituted pyrrolizidine endo-20b, obtained through the 
same process but using (E)-1,2-bis(phenylsulfonyl)ethylene 
(BPSE) as dipolarophile, was isolated in moderate 54% yield as 
only one stereoisomer as well (Scheme 6). The effect of the 
addition of silver acetate (Method B) was only tested in the 
multicomponent cycloaddition involving the disulfone with the 
aim to increase the yield, but any improvement was observed. 
Again, the prevalence of the α-attack of the corresponding S-
shape dipole A (Figure 3) was the driving force of the 
generation of pure endo-stereoisomers 20, the dipolarophile 
being approached by the same face where the hydroxy group is 
located. The assignment of the absolute configuration of the 
major compounds endo-20 done by the intensity of the nOe 
HC5→CO2Me  bonded to the quaternary centre in both molecules 
following  the same approach observed for molecules 19a.  
 
 
Scheme 6. Multicomponent 1,3-DC of (2S,4R)-4-hydroxyproline methyl 
ester hydrochloride 14, benzaldehyde and different dipolarophiles. 
 
Attempts to introduce an aliphatic aldehyde such as ethyl 
glyoxylate using both methods, were unfruitful. On the other 
hand, when 14, triethylamine, isovaleraldehyde, and tert-butyl 
acrylate were allowed to react in toluene only the Michael-type 
addition adduct 21 (Figure 5) was obtained in 84% yield. 
 
Figure 5. Michael-type adduct 21 isolated in the reaction of 14 with 
isovaleraldehyde and tert-butyl acrylate. 
 
Analogously, optically pure polysubstituted proline methyl 
ester derivative 16, obtained according to the literature using a 
chiral binap·silver(I) perchlorate complex,35 was also appropriate 
to complete the titled multicomponent 1,3-DC with NPM and 
cinnamaldehyde at 70 ºC. In this reaction the 9:1 endo-22a:exo-
22a ratio was isolated in 76% chemical yield (Scheme 7). The 
presence of both substituents at 2- and 5-positions of the starting 
proline derivative 16 avoided the approach of the aldehyde when 
the reaction was carried out at room temperature, so a higher one 
(70 ºC) is needed.  The detection of the major endo-isomer and a 
small amount of the exo-adduct was also possible by the analysis 
of the crude 1H NMR spectra. The relative configuration of all 
products obtained and described in this section was established 
according to nOe experiments, especially crucial being the 
intensity of the nOe of the three HC5 HC4 HC3→CO2Me bonded to 
the quaternary centre. 
H
O
Ph
70 °C
16
endo-22a:exo-22a 9:1 dr
N
CO2MePh
OO
N
N
N
CO2Me
Ph
Ph
O
O
OO
Ph
N
H
N Ph
O
O
76%
AgOAc (5 mol%)
PhCH3, 17h
3
4
5
 
Scheme 7. Multicomponent 1,3-DC of enantiomerically enriched prolinate 
methyl ester 16 with benzaldehyde and NPM. 
 
Absolute or relative configurations of all products were 
assigned on the basis of X-ray diffraction analysis (for a small 
number of molecules, see text), and NMR experiments (see 
supporting information).  
 
2.2. Multicomponent 1,3-DC with proline ester hydrochlorides 
17 and 4-thiaproline 18 
The synthesis of pyrrolizidines 23 was initially tested at room 
temperature employing an analogous multicomponent process as 
described in the previous section. In this case, (S)-proline methyl 
ester hydrochloride 17a was allowed to react with 
cinnamaldehyde and methyl acrylate in the presence of 
triethylamine (1 equiv). Although the reaction was slower in 
toluene (5 h) than in DCM or THF with methyl acrylate, pure 
23aa (1H NMR) was obtained in 96% yield. Therefore, this 
solvent was selected again because a higher diastereoselection 
(99:1) was obtained than with DCM or THF (Scheme 8). In this 
transformation the presence of the benzyl or methyl ester in the 
starting proline was not very noticeable in terms of the final 
diastereoselection, although endo-23ba was obtained in a higher 
93% yield (Scheme 8). The presence of the silver salt (method B) 
afforded analogous results than the reaction performed without 
metal catalysis. 
Based on the X-ray diffraction analysis of molecule endo-
23aa,26 we  could justify its formation through a preferential α-
attack of the less sterically hindered S-shape dipole B (Figure 6). 
The approach of the acrylate took place in an endo-manner such 
as it was described in the reactions performed with the 
enantiomerically pure 4-hydroxyproline derivative 14. Also, in 
this case, nOe, and bidimensional experiments and analysis of the 
corresponding 1H NMR coupling constants confirmed the 
proposed structure for these compounds endo-23. This preference 
of the trans-2,5-relative configuration (according to the same 
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proline III nomenclature, Figure 4) was also confirmed for 
these multicomponent transformations.  
 
Scheme 8. Multicomponent 1,3-DC of proline ester hydrochlorides 17, 
cinnamaldehyde and methyl acrylate. 
 
 
Figure 6. Intermediate 1,3-dipoles B derived from proline esters 17. 
 
The study of the presence of α- or β-substituents in the acrylate 
moiety was carried out employing allyl methacrylate and (E)-3-
(but-2-enoyl)oxazolidin-2-one, respectively. Both dipolarophiles 
afforded pyrrolizidines 23ab and 23ac as unique 
diastereoisomers in excellent chemical yields (Scheme 9). The 
role of silver acetate was negligible and the position of the 
substituents of acrylates did not produce any significant steric 
hindrance. The assignment of the relative configuration of the major 
racemic form 23ab and 23ac was done according to the chemical 
shift of the CHN signal (≥4.2 ppm). Unfortunately, the intensity of 
the nOe HC5→CO2Me bonded to the quaternary centre was very 
weak, nevertheless an important nOe was detected in HC5→Me of 
each cycloadduct. 
 
Scheme 9. Multicomponent 1,3-DC of proline methyl ester hydrochloride 
17a, cinnamaldehyde and α,β-unsaturated carbonyl compounds. 
 
When NMM was tested with both methyl and benzyl 
prolinates, after 2 h of reaction time, a similar dr was obtained, 
but compounds endo-23ad and exo-23ad were isolated as cleaner 
crude products (1H NMR spectroscopy) than the reaction 
involving proline 17b (Scheme 10). According to precedent 
results, the endo-approach through the α-attack promoted by S-
shape dipole B (Figure 6) was preferred in all cases assayed. In 
the case of final cycloadducts 23ad and 23bd the chemical shift  
CHN signal (≥4.3 ppm) corresponded to the exo-adduct, presumably 
due to the more restricted fused-tricyclic skeleton. The intensity of 
the nOe HC5→CO2Me and nOe HC5→CO2CH2 was noticeable, and 
also very high increment of population was detected in HC6 upon 
irradiation of HC5 atom in both molecules.  
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Scheme 10. Multicomponent 1,3-DC of proline ester hydrochlorides 17, 
cinnamaldehyde and NMM. 
Dimethyl fumarate offered a similar behavior in terms of 
diastereoselectivity (85:15) and chemical yields (83%). By using 
methods A and B, the most stable endo-23ae was the major 
diastereoisomer according to an endo-approach (Scheme 11).36 
For racemic form endo-23ae the chemical shift of the CNH signal 
was 4.3 ppm whilst for the minor exo-adduct was 4.1 ppm. In this 
mixture, nOe experiment was not useful.  
 
Scheme 11. Multicomponent 1,3-DC of proline methyl ester hydrochloride 
18a, cinnamaldehyde and dimethyl fumarate. 
On the other hand, when β-nitrostyrene was employed as 
dipolarophile, together with proline methyl ester hydrochloride 
17a and cinnamaldehyde, a different regio and stereochemical 
outcomes were observed. The major endo-cycloadduct 23af was 
obtained with regioisomer 24af (85:15 rr), which could be 
isolated in 79% and 10% yield, respectively (Scheme 12). A 
plausible explanation for the formation of this new regioisomer 
(not detected with other dipolarophiles) can be attributed to the 
lowest LUMO energy and high reactivity of the nitroalkene, 
which was able to trap the small amount of the S-shape dipole B 
reacting by its γ-position (Figure 6). 1H NMR spectra of endo-
cycloadduct 23af shown CHN signal at 4.8 ppm and CHNO2 at 
6.1 ppm. A very intense nOe effect was observed between these 
two hydrogen atoms (15% aprox.), and a positive small nOe HC5 
HC4 PhC3→CO2Me. In regioisomer 24af HC3→CO2Me and HC3→ 
HC5 positive nOe were observed. 
 
Scheme 12. Multicomponent 1,3-DC of proline methyl ester 
hydrochloride 17a, cinnamaldehyde and β-nitrostyrene. 
 
Phenyl vinyl sulfone furnished one diastereoisomer endo-23ag 
in 71% with a small amount o other stereoisomer (Scheme 16), 
whilst BPSE gave a very complex reaction mixture of products, 
from which endo-23ah and exo-23ah could be isolated in 69% 
overall yield (Scheme 13). The presence of the silver acetate (5 
mol%) made the reactions slower giving the same results. The 
regio- and stereochemistry of the processes involving alkenyl 
sulfones followed the general pattern of reactivity controlled by 
α-attack of the S-shape dipole B (Figure 6). In the reaction 
dealing with BPSE an additional non-identified cycloadduct (ca. 
19%) was observed in the crude NMR spectra which could not be 
isolated after flash chromatography. The relative configuration 
was established according to the results given by nOe 
experiments. 
NH
CO2Me O H
17a Ph
Toluene
Et3N, rt
 HCl
Method A: 3 h
Method B: AgOAc (5 mol%), 8-9 h
Method A: 71%, endo-23ag 99:1 dr
Method B: 8 h, 69%, endo-23ag 99:1 dr
N
MeO2C
Ph
endo-23ag
endo-23ah
N
MeO2C
Ph
exo-23ah
+
SO2Ph
R
SO2Ph
R R
SO2Ph
R = H
R = SO2Ph
Method A: 85%, endo-23ah:exo-23ah 78:12 dr
Method B: 9 h, 72%, endo-23ah:exo-23ah 72:28 dr
+ +
 
Scheme 13. Multicomponent 1,3-DC of proline methyl ester hydrochloride 
17a, cinnamaldehyde and vinyl sulfones. 
 
The use of crotonaldehyde instead of cinnamaldehyde in the 
multicomponent reaction of 17a together with acrylates was 
evaluated. In general, the α-attack of the dipole was preferred. 
Methyl acrylate did not give as good diasteresoselectivity for 
endo-25aa (Scheme 14) than in the case of using 
cinnamaldehyde (Scheme 9). However, a very important 
difference was found when allyl methacrylate was attempted. 
Here, when method A was attempted the reaction gave a poor 
diastereoselection but the presence of AgOAc gave rise to an 
excellent endo-diastereoselectivity (98%) of the pyrrolizidine 
endo-25ab, which was isolated in 85% yield (Scheme 14). Again, 
HC5 HC4→CO2Me, HC4→ HC5 and HC5→Me positive nOe were 
crucial for the assignment of the relative configuration not only for 
cycloadducts 25, but for pyrrolizidines endo-26 and endo-28. 
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Scheme 14. Multicomponent 1,3-DC of proline methyl ester hydrochloride 
17a, crotonaldehyde and α,β-unsaturated esters. 
 
Benzaldehyde induced the formation of the expected endo-
26aa but also the corresponding unidentified regioisomer 27aa 
through the described α- and γ-attack relative to S-shape B 
dipole, respectively (Figure 6) in both silver-catalyzed and non-
catalyzed processes involving proline ester 17a and methyl 
acrylate. In these two examples the conversion and chemical 
yield of compound 26aa were similar independently of the 
method employed (Scheme 15). By contrast, isovaleraldehyde 
derived ylide reacted exclusively through an α-attack of the S-
shape B dipole (Figure 6), giving access to pyrrolizidine endo-
28aa and other non-identified byproducts only in the presence of 
silver acetate (Scheme 15). 
 
 
Scheme 15. Multicomponent 1,3-DC of proline methyl ester hydrochoride 
17a,  benzaldehyde or isovaleraldehyde and methyl acrylate. 
According to the experience acquired in this type of 
multicomponent reaction using acyclic α-amino esters, 
dipolarophiles and ethyl glyoxylate,29 we used this aldehyde for 
the synthesis of more functionalized pyrrolizidines 29 and 30 
(Schemes 16 and 17). The domino process took place exclusively 
under silver-promoted catalysis in 1 d at room temperature in all 
examples tested, otherwise the reaction completely failed. The 
domino sequence involving acrylates afforded relevant outcomes. 
When methyl acrylate was used compound exo-29aa was isolated 
as only one regio- and diastereoisomer in 59% yield (Scheme 
16). The same exo-30ab product was the major isolated regio- 
and diasteroisomer when the reaction was performed with allyl 
methacrylate. In this example, the endo-cycloadduct 29ab (until 
now, the most favored cycloadduct in precedent reactions with 
conjugated, aromatic and aliphatic aldehydes) was also generated 
but in lower proportions (Scheme 17). An explanation for 
justifying the driving force responsible of the observed 
regioselectivity in these particular examples can be due to the 
presence of the ethoxycarbonyl group incorporated during the 
formation of the iminium salt. This electron withdrawing group 
competed with the methoxycarbonyl unit of the starting proline 
ester in the stabilization of the negative charge of the dipole C 
(Figure 7). The highest stability of the inner ring double bond in 
dipoles C, with respect to the outer ring alkene, allowed a 
preferential γ-attack of the named dipole affording a 2,5-trans-
relative configuration of both ester groups via the γ-attack of the 
less sterically hindered S-shape dipole C (Figure 7). Besides, the 
exo-approach occurred because a stereoelectonic effect between 
both ester groups of the dipolarophile and proline components 
partially avoided the endo-approach.29 This last hypothesis can be 
supported by the result generated from the cycloaddition using 
allyl methacrylate. In this way, allyl ester favored in lesser 
extension the generation of exo-29ab giving a larger amount of 
endo-30ab. Both positive HC5→CO2Me bonded to the quaternary 
C2 and CO2Me→CO2Me nOe effects and negative HC3→HC5 or  
MeC3→HC5 justified the proposed relative configuration for 
pyrrolizidine exo-29a.  
 
 
Scheme 16. Multicomponent 1,3-DC of proline methyl ester hydrochloride 
17a, ethyl glyoxylate and acrylates. 
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Figure 7. Intermediate 1,3-dipoles C derived from proline ester 17a and 
ethyl glyoxylate. 
 
Under the same reaction conditions, dimethyl fumarate 
afforded compounds exo-29ac and endo-29ac in 82% yield and 
with a high regioisomeric ratio (98:2, Scheme 17). This result 
also supported the explanation given above for the reaction of 
proline methyl ester, ethyl glyoxylate and acrylates. NOESY 
experiment, together with another bidimensional NMR spectra 
helped us to discard the endo-29ac relative configuration 
corresponding to the major isolated product. 
 
 
Scheme 17. Multicomponent 1,3-DC of proline methyl ester hydrochloride 
17a, ethyl glyoxylate and dimethyl fumarate. 
 
The study of the scope of these transformations was finished 
testing 4-thiaproline methyl ester hydrochloride 18 as dipole 
precursor together with cinnamaldehyde and NMM. The result of 
this reaction performed at room temperature was satisfactory 
giving a 63% yield of a 5:1 endo-31:exo-31 dr (Scheme 18). The 
positive nOe HC5→ HC4 HC3 CO2Me allowed us to assign the 
drawn structure for cycloadduct endo-31. 
 
Scheme 18. Multicomponent 1,3-DC of 4-thiaproline methyl ester 
hydrochloride 18, cinnamaldehyde and NMM. 
 
2.3 Computational studies 
In order to further understand and rationalize the high 
diastereoselectivity observed experimentally in the 
multicomponent [3+2] reactions described in this work, we 
decided to perform several DFT calculations. As model case 
studies, we selected the reaction between cinnamaldehyde, NMM 
and the selected proline derivatives 14, and 17a. In addition, the 
diverse regioselectivity observed on the reaction of 
cinnamaldehyde, 17a and β-nitrostyrene as dipolarophile was 
also analyzed.  
Analysis of the azomethyne ylides derived from 
cinnamaldehyde and 14 or 17a. Initially, we analyzed the S-
shape and U-shape related to the isomerization processes of the 
1,3-dipoles s-32 and s-33 derived from cinnamaldehyde and the 
proline esters 14 or 17a, respectively. The results are collected in 
Table 1 and Figure 8. 
 
Table 1. Activation and reaction Gibbs free energies associated with the 
isomerization processes of S- and U-shaped azomethine ylides 32 and 33 
derived from cinnamaldehyde and proline derivatives 14 or 17a, respectively. 
Values computed at M06-2X(PCM)/def2-TZVPP//B3LYP(PCM)/6-31G* 
level of theory.  
 
 
entry Compound Proline 
derivative 
∆Ga 
(kcal mol-1) 
∆GRXN 
(kcal mol-1) 
1 s-32 14 +32.3 +2.3 
2 s-33 17a +31.4 +0.5 
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Figure 8. Main geometrical features of the transition structures associated 
with the isomerization of s-32 (TSROTa) and s-33 (TSROTb) computed at 
B3LYP (PCM) /6-31G* level of theory. Dihedral angles (θabcd, absolute 
value), are in deg. 
 
These calculations indicated that the isomerization processes of 
s-32 and s-33 azomethine ylides present an activation barrier 
higher than 30 kcal mol-1, which is unreachable at room 
temperature. Moreover, the U-shaped azomethine ylides are less 
stable than their S-shaped counterparts due to steric clash 
between cinnamaldehyde chain and ester moieties. On the basis 
of these results, we concluded that formation of u-32 or u-33 is 
neither kinetically nor thermodynamically favored. Therefore, 
only S-shaped azomethine ylides will be considered in the next 
calculations. 
We also analyzed the frontier molecular orbitals (FMO) of s-32 
and s-33. In this manner, it is feasible to understand the 
preference for α- or γ-attacks experimentally observed (Figure 9). 
 
 
Figure 9. Frontier molecular orbitals (FMO) and NBO charges (in 
brackets) of azomethine ylides s-32 and s-33 computed at the B3LYP/6-31G* 
level of theory. Expansion orbital coefficients on Cα and Cγ atoms computed 
at RHF/AM1 level are also included. 
 
The computed FMO of azomethine ylides s-32 and s-33 are 
quite similar in shape. The analysis of the atomic expansion 
coefficients in the relevant FMO revealed no significant 
differences between both ylides. Moreover, in all cases, the 
expansion coefficient on Cα is higher than on Cγ . It is well 
known that in a concerted 1,3-DC reaction, the cyclic electronic 
circulation requires the participation of two stabilizing 
interactions between the relevant FMO of the azomethine ylides 
and the dipolarophiles, namely HOMOylide-LUMOdipolarophile and 
HOMOdipolarophile-LUMOylide.37 In the case of unsymmetrical 
dipolarophiles, the product with the maximum orbital overlap, 
that is, the α-product, will be formed due to a favored cyclic 
electronic circulation.38 Therefore, a similar preferential 
regioselectivity in the [3+2] cycloadditions can be expected for s-
32 and s-33 ylides, since the atomic expansion coefficients are 
almost equal for a given atom. 
If we assume an stepwise 1,3-DC reaction, the accepted 
mechanism consists of an addition of the 1,3-dipole on the 
dipolarophile to form a zwiterionic intermediate, followed by a 
ring closure step. Thus, in the case of non-symmetrical 
dipolarophiles, the negatively charged carbon atom of the 
azomethine ylide would preferentially react in the first step with 
the dipolarophile in a Michael-like fashion. The computed NBO 
charges on Cα and Cγ are different in the selected azomethine 
ylides. In the case of s-32, the negative charge is placed on Cα, 
whereas in s-33 it is placed on Cγ. Therefore, electrostatic 
arguments point to different regioselectivities for s-32 and s-33 
(Scheme 19). 
 
 
Scheme 19. Preferred regiochemistry expected on the 1,3-DC of 
azomethine ylides considering the initial Michael-like first step of an stepwise 
mechanism where the negative charge is placed on (A) Cα (α-attack) or (B) 
Cγ (γ-attack). Z represents an electron-withdrawing group. 
 
In the case of azomethine ylide s-32, both scenarios predict the 
exclusive formation of the α-attack, in good agreement with the 
experimental results. On the other hand, in the case of s-33, the 
preference for the possible attacks results from a compromise 
between the effective orbital overlap between reagents associated 
with a pericyclic concerted mechanism, which favors the α-
attack, and the unsymmetrical electron density distribution on Cα 
and Cγ in the azomethine ylides which favors the γ-attack. This 
observation is in good agreement with the low regioselectivity 
observed in the experimental reaction of s-33 with β-nitrostyrene 
(Scheme 12).  
Multicomponent 1,3-DC of cinnamaldehyde, NMM and 14 or 
17a. We also computed all the stationary points associated with 
the cycloaddition reaction between NMM and s-32 or s-33. The 
results are collected in Table 2 and Figure 10. 
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Table 2. Computed activation and reaction Gibbs free energies of the [3+2] 
cycloadditions of S-shaped azomethine ylides s-32 and s-33 with NMM at 
M06-2X(PCM)/def2-TZVPP//B3LYP(PCM)/6-31G* level of theory. 
entry ylide  cycloadduct ∆Ga  
(kcal mol-1) 
∆GRXN 
(kcal mol-1) 
1 
s-32 
endo endo-19e +4.1 -29.8 
2 endo’ endo-19e’ +7.8 -30.0 
3 exo exo-19e +11.3 -30.3 
4 exo’ exo-19e’ +9.8 -30.3 
5 
s-33 endo endo-23ad +5.0 -30.6 6 exo exo-23ad +6.4 -29.8 
 
 
Figure 10. Main geometrical features and relative energies of the transition structures 
associated with the [3+2] cycloadditions of NMM with azomethine ylides (A) s-32 or 
(B) and s-33 computed at M06-2X(PCM)/def2-TZVPP//B3LYP(PCM)/6-31G* level of 
theory. Relative energies are given in kcal mol-1 and bond distances are in Å. 
 
In the case of hydroxyproline azomethine ylide s-32, our 
calculations show that the reaction is an exothermic process with 
a high preference for endo-19e cycloadduct formation (Table 2, 
entries 1-4). The computed activation barrier associated with this 
product is at least ca. 4 kcal mol-1 lower than those associated 
with the formation of cycloadducts endo-19e’, exo-19e and exo-
19e’. Moreover, it can be observed in Figure 10A, that the all the 
computed transition structures are concerted but quite 
asynchronous. The different distances for the two C-C bonds 
being formed are compatible with an α-attack of the iminium-
enolate structure to NMM (Figure 3). In contrast, in the most 
energetic transition structure (TSexoa) there is an inversion on the 
relative C-C distances, which corresponds to a γ-attack. 
Our calculations indicate that endo-19e will be predominantly 
formed because of a favorable hydrogen bonding between the 
hydroxy group and the incoming dipolarophile, which is not 
possible in any of the other possible approaches. Moreover, a 
general preference of the endo-cycloadditions over the exo-
approaches was observed, probably because of the presence of 
stabilizing coulombic and secondary orbital interactions in the 
former. Our computational results predict a theoretical 
diastereomeric ratio of 98:2:0:0 of cycloadducts endo-19e:endo-
19e’:exo-19e:exo-19e’, in excellent agreement with the 
experimental results (Scheme 5).  
Reaction of NMM with proline methyl ester derivative s-33 
was also considered. In this case, the computed activation 
barriers and reaction Gibbs free energies are similar to these 
computed for s-32 (Table 2, entries 5-6). However, the energetic 
difference between the endo- and exo- approaches is lower due to 
less congested substitution pattern in the pyrrolidine moiety. As 
in the previous case, the computed transition structures were 
found to be concerted but asynchronous. Remarkably, in the 
transition structure associated with the lowest energy barrier 
(TSendob), the relative C-C distances correspond to a α-attack 
whereas in TSexob, these distances correspond to a γ-attack 
(Figure 10B). The computed endo-23ad:exo-23ad ratio 
associated with this process is 90:10, in nice agreement with the 
experimental results. 
Reaction of cinnamaldehyde, β-nitrostyrene and 17a. The 
anomalous regioselectivity achieved in the reaction of 
cinnamaldehyde, 17a and β-nitrostyrene as dipolarophile called 
our attention. The activation and reaction Gibbs free energies, as 
well as the main geometrical features of the transition structures 
were calculated and are collected in Table 3 and Figure 11, 
respectively. 
Table 3. Computed activation and reaction Gibbs free energy on the [3+2] 
cycloadditions of s-33 with β-nitrostrene computed at M06-2X(PCM)/def2-
TZVPP//B3LYP(PCM)/6-31G* level of theory. 
entry ylide  cycloadduct ∆Ga  
(kcal mol-1) 
 ∆GRXN  
 (kcal mol-1) 
1 
s-33 
endo endo-23af +3.2 -23.6 
2 endo-24af +4.6 -22.3 
3 exo exo-23af +8.4 -24.2 
4 exo-24af +11.0 -24.2 
 
 
Figure 11. Main geometrical features and relative energies of the transition 
structures associated with all the possible [3+2] cycloadditions of s-33 with 
β-nitrostrene computed at M06-2X(PCM)/def2-TZVPP//B3LYP(PCM)/6-
31G* level of theory. Relative energies are given in kcal mol-1 and bond 
distances are in Å. 
 
In this case, we observed that the formation of endo-23af had 
an associated activation barrier of 1.4 kcal mol-1 lower than that 
associated with the formation of its regioisomer endo-24af (Table 
3). Moreover, formation of exo-analogues was kinetically 
disfavored. In addition, the transition structures were found to be 
more asynchronous than in the previous cases, in which the 
symmetrical NMM was used as dipolarophile. In these reactions, 
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higher differences between the C-C distances associated with 
the two new σ-bonds were obtained (Figures 10 and 11). The 
kinetic product distribution computed for this reaction was 90:10 
for the endo-23af:endo-24af cycloadducts, associated with α- 
and γ-attacks, respectively, in good agreement with the 
experimental results. 
Conclusions 
In conclusion, a very efficient and mild multicomponent 
diastereoselective 1,3-DC of (2S,4R)-4-hydroxyproline methyl 
ester and other similar systems, proline and 4-thiaproline esters, 
aldehydes and dipolarophiles have been optimized for the final 
synthesis of polysubstituted pyrrolizidine alkaloids. The analysis 
of the general scope of the reaction allowed to direct the attack of 
the in situ formed 1,3-dipole. The α-attack is favored when 
conjugated, aromatic, and aliphatic aldehydes were used, whereas 
a favored γ-attack occurs with ethyl glyoxylate. In this last 
example the role of the silver salt was crucial, otherwise the 
reaction did not take place at all in its absence. With other 
aldehydes the presence of silver was not necessary except in the 
case of working with proline methyl ester and BPSE as 
dipolarophile and in the reactions involving crotonaldehyde and 
methyl acrylate. In all cases, 2,5-trans-relative configuration 
between two electron-withdrawing groups was achieved and 
major endo-selectivity (2,4-cis-relative configuration) was a 
typical feature of these transformations in the absence or in the 
presence of silver acetate. However, an exo-selectivity was 
mainly found when ethyl glyoxylate participated in the reaction 
mixture affording 2,3-cis and 2,5-trans-relative configuration. 
These new highly functionalized pyrrolizidines can have 
potential biological activity.  
Computational studies show that the driving force underlying 
the high diastereoselection found for the [3+2] cycloadditon of 
hydroxyproline derivatives is a consequence of a hydrogen 
bonding that cannot be formed in the other approaches. In the 
case of proline esters, the observed lower diastereoselection is 
consequence to the lack of substituents on the pyrrolidine ring, 
being the endo-approach the energetically favored process. The 
anomalous regioselectivity found in the reaction of 
cinnamaldehyde, β-nitrostyrene and 17a was found to be a 
consequence of a trade off between an efficient orbital overlap 
and the existence of different electron densities on Cα and Cγ  
centers. In all the cases studied, the computational results were 
found to be in good agreement with the experimental data. 
Experimental Section 
1. General.  
Aldehydes were distilled prior to use for the elaboration of the iminoesters. 
Melting points were determined with a hot plate apparatus and are 
uncorrected. Only the structurally most important peaks of the IR spectra 
are listed. 1H NMR (300 MHz) and 13C NMR (75 MHz) spectra were 
obtained using CDCl3 as solvent and TMS as internal standard, unless 
otherwise stated. Low-resolution electron impact (EI) mass spectra were 
obtained at 70eV and high-resolution mass spectra were recorded with 
accurate mass assignments better than 2 ppm. Microanalyses were 
performed selecting the appropriate standard compound. Analytical TLC 
was performed on silica gel plates and the spots were visualized under UV 
light (λ = 254 nm). For flash chromatography we employed silica gel 60 
(0.040-0.063 mm). Complexes were prepared according to the reported 
procedure (see text). All of the transformations performed with silver 
catalysts were performed in the absence of light. All diastereomeric ratios 
were determined by 1H NMR spectroscopy of the crude reaction mixture, 
and by weighting each stereoisomer after separation by flash 
chromatography.  
Density Functional Theory39 (DFT) geometry optimizations and harmonic 
analyses were performed using the hybrid B3LYP40 functional. Relative 
energies were computed by means of single point calculations on the 
optimized geometries using the M06-2X41 functional. This M06-2X//B3LYP 
hybrid theoretical level was chosen since it is known that B3LYP and M06-
2X produce similar optimized geometries in this kind of reactions.42 
Moreover, the latter highly parameterized M06-2X method is well suited for 
the treatment of nonbonding interactions and dispersion forces.43 The 6-
31G* and def2-TZVPP basis sets were used. Solvent effects were 
computed by means of PCM method using toluene as solvent.44 Reactants 
and products showed positive definite Hessians. Transition structures 
(TSs) showed one and only one imaginary frequency associated with 
nuclear motion along the chemical transformation under study. Free 
energies at 298.15 K were calculated by including the corresponding 
thermal corrections to Gibbs free energies (TCGE). Figures including 
optimized structures were made with Maestro.45 FMO representations were 
prepared using Gauss-view interface.46 Expansion coefficients were 
calculated using the AM147 semiempirical Hamiltonian. 
 
2. General procedure for the synthesis of cycloadducts in the absence of 
AgOAc. 
Methyl ester L-proline hydrochloride (82.8 mg, 0.5 mmol) or L-4-
hydroxyproline methyl ester hydrochloride (92.1 mg, 0.5 mmol),the 
corresponding alkene (0.5 mmol), the aldehyde (0.5 mmol) and 
triethylamine (90 µL, 0.55 mmol) were dissolved in toluene (3 mL). The 
resulting mixture was stirred for times described across the main text. Then 
the solvent was evaporated under reduced pressure and the residue was 
purified by flash chromatography (silica gel) to afford the corresponding 
product. 
3. General procedure for the synthesis of cycloadducts in the presence of 
AgOAc. 
Methyl ester L-proline hydrochloride (82.8 mg, 0.5 mmol) or L-4-
hydroxyproline methyl ester hydrochloride (92.1 mg, 0.5 mmol), or chiral 
polysubstituted prolinates (0.5 mmol)silver acetate (4.15 mg, 0.025 mmol), 
the corresponding alkene (0.5 mmol), the aldehyde (0.5 mmol) and 
triethylamine (90 µL, 0.55 mmol) were dissolved in toluene (3 mL). The 
resulting suspension was stirred for the corresponding time and 
temperature (see main text) avoiding the light exposure. Then the solvent 
was evaporated under reduced pressure and the residue was purified by 
flash chromatography (silica gel) to afford the corresponding product.  
Compounds 20b, exo-23bd, endo-23ae, endo-23ag, endo-25aa, and exo-
29ab were unpurified with small unidentified substances (see spectra). 
4. Physical and spectroscopic data of compounds 
 
Dimethyl (2S,3S,6R,7aS)-6-hydroxy-3-[(E)-styryl]hexahydro-1H-pyrrolizine-
2,7a-dicarboxylate 19a:27 Brown needles, 117 mg (68%), mp: 99-102 ºC; 
= +81.2 (c 1, CHCl3); IR (neat)  νmax 3322, 2950, 2305, 1715, 1707 
cm-1; 1H NMR δH: 1.97 (dd, J = 13.5, 4.8 Hz, 1H, CHHCCO2Me), 2.42 
(deform. dd, J = 12.9, 12.3 Hz, 1H, CHHCHCO2Me), 2.54-2.61 (m, 2H, 
CHHCHCO2Me, CHHCCO2Me), 3.07-3.16 (m, 2H, CH2N), 3.50-3.56 (m, 
4H, CHCO2Me, CHCO2CH3), 3.73 (s, 3H, CCO2CH3), 4.21 (dd, J = 10.3, 
7.8 Hz, 1H, CHN), 4.56 (deform. dddd, J = 5.1, 5.0, 4.8, 4.7 Hz, 1H, 
CHOH), 6.23 (dd, J = 15.5, 10.4 Hz, 1H, CHCHN), 6.51 (d, J = 15.5 Hz, 
1H, CHPh), 7.23-7.38 (m, 5H, ArH); 13C NMR δC: 36.9 (CH2CCO2Me), 45.0 
(CH2CHCO2Me), 50.5 (CHCO2Me), 51.9 (CCO2CH3), 52.7 (CHCO2Me), 
56.2 (CH2N), 66.9 (CHN), 74.2 (CHOH), 75.9 (CCO2Me), 126.7, 128.0, 
128.7, 136.7 (ArC), 127.5 (CHCHN), 136.7 (CHPh), 172.4 (CHCO2Me), 
176.5 (CCO2Me); MS (EI-GC) m/z: 345 (M+, <1%), 269 (11), 268 (100), 
243 (11), 241 (15), 209 (15), 126 (11), 105 (13); Microanalysis calculated 
for C19H23NO5: C, 66.1; H, 6.7; N, 4.1%; found: C, 66.5; H, 7.0; N, 4.3%. 
Dimethyl (2R,3R,6R,7aR)-6-hydroxy-3-[(E)-styryl]hexahydro-1H-pyrrolizine-
2,7a-dicarboxylate 19a´:27 Brown needles, 29 mg (17%), mp: 95-97 ºC; 
= +34.7  (c 1, CHCl3); IR (neat)  νmax 3396, 2944, 2315, 1717, 1698 
cm-1; 1H NMR δH: 2.06 (dd, J = 14.0, 6.1 Hz, 1H, CHHCCO2Me), 2.24 (dd, 
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J = 13.4, 11.7 Hz, 1H, CHHCHCO2Me), 2.50 (dd, J = 14.0, 1.8 Hz, 1H, 
CHHCCO2Me), 2.63 (dd, J = 13.4, 7.0 Hz, 1H, CHHCHCO2Me), 2.92 (dd, J 
= 11.7, 2.5 Hz, 1H, CHHN), 3.50-3.53 (m, 4H, CHCO2Me, CHCO2CH3), 
3.76 (s, 3H, CCO2CH3), 4.16 (dd, J = 10.4, 7.4 Hz, 1H, CHN), 4.44 (m, 1H, 
CHOH), 5.87 (dd, J = 15.6, 10.4 Hz, 1H, CHCHN), 6.57 (d, J = 15.5 Hz, 
1H, CHPh), 7.27-7.31 (m, 5H, ArH); 13C NMR δC: 36.9 (CH2CCO2Me), 46.5 
(CH2CHCO2Me), 50.7 (CHCO2Me), 52.0 (CCO2CH3), 53.0 (CHCO2Me), 
57.0 (CH2N), 66.5 (CHN), 75.0 (CHOH), 75.5 (CCO2Me), 125.3 (CHCHN), 
126.7, 128.2, 128.8, 136.3 (ArC), 136.0 (CHPh), 172.3 (CHCO2Me), 177.3 
(CCO2Me); MS (EI-GC) m/z: 345 (M+, <1%), 269 (13), 268 (100), 243 (10), 
241 (31), 209 (22), 105 (11), 59 (10); Microanalysis calculated for 
C19H23NO5: C, 66.1; H, 6.7; N, 4.1%; found: C, 66.4; H, 6.9; N, 4.1%. 
Dimethyl (2S,3S,6R,7aS)-6-[(tert-butyldimethylsilyl)oxy]-3-[(E)-
styryl]hexahydro-1H-pyrrolizine-2,7a-dicarboxylate 19b:27 Sticky orange oil, 
143 mg (62%); = +4.2  (c 1, CHCl3); IR (neat)  νmax 3396, 2944, 
2315, 1717, 1698 cm-1; 1H NMR δH: -0.04 (s, 6H, OTBS), 0.81 (s, 9H, 
OTBS), 1.95 (dd, J = 13.0, 6.0 Hz, 1H, CHHCCO2Me), 2.28 (deform. dd, J 
= 13.2, 13.0 Hz, 1H, CHHCHCO2Me), 2.40-2.51 (m, 2H, CHHCHCO2Me, 
CHHCCO2Me), 2.8 (dd, J = 11.6, 4.7 Hz, 1H, CHHN), 3.20 (dd, J = 11.6, 
5.4 Hz, 1H, CHHN), 3.49-3.56 (m, 4H, CHCO2Me, CHCO2CH3), 3.74 (s, 
3H, CCO2CH3), 4.18 (dd, J = 10.5, 7.2 Hz, 1H, CHN), 4.56 (deform. dddd, J 
= 6.0, 5.4, 5.3, 4.7 Hz, 1H, CHOH), 5.85 (dd, J = 15.6, 10.5 Hz, 1H, 
CHCHN), 6.54 (d, J = 15.6 Hz, 1H, CHPh), 7.24-7.30 (m, 5H, ArH); 13C 
NMR δC: -4.8, -4.9 (OTBS), 18.2 (OTBS), 25.9 (OTBS), 37.5 
(CH2CCO2Me), 46.4 (CH2CHCO2Me), 49.4 (CHCO2Me), 51.9 (CCO2CH3), 
52.7 (CHCO2Me), 56.3 (CH2N), 66.9 (CHN), 74.5 (CHOH), 74.7 (CCO2Me), 
125.4 (CHCHN), 126.7, 128.2, 128.7, 136.4 (ArC), 136.0 (CHPh), 171.9 
(CHCO2Me), 176.9 (CCO2Me); MS (EI-GC) m/z: 459 (M+, <1%), 327 (10), 
268 (100), 267 (11), 243 (15), 242 (10), 241 (21), 209 (17), 208 (10), 106 
(10), 105 (10);  HRMS calculated for C25H37NO5Si +1: 460.2519; found: 
460.2522. 
Endo-19b’ could not be separated. 
2-tert-Butyl 7a-methyl (2S,3S,6R,7aS)-6-hydroxy-3-[(E)-styryl]hexahydro-
1H-pyrrolizine-2,7a-dicarboxylate 19c:27 Sticky yellow oil, 112 mg (81%); 
= -124.7   (c 1, CHCl3); IR (neat)  νmax 2985, 2939, 2305, 1714, 
1691 cm-1; 1H NMR δH: 1.26 [s, 9H, CO2C(CH3)3], 1.94 (dd, J = 13.4, 5.1 
Hz, 1H, CHHCCO2Me), 2.37 (deform. dd, J = 12.6, 12.3 Hz, 1H, 
CHHCHCO2But), 2.50-2.59 (m, 2H, CHHCHCO2But, CHHCCO2Me), 3.08-
3.15 (m, 2H, CH2N), 3.44 (ddd, J = 12.3, 7.5, 6.7 Hz, 1H, CHCO2But),   
3.72 (s, 3H, CCO2CH3), 4.16 (dd, J = 10.4, 7.5 Hz, 1H, CHN), 4.54 
(deform. dddd, J = 5.5, 5.3, 5.1, 4.9 Hz, 1H, CHOH), 6.24 (dd, J = 15.6, 
10.4 Hz, 1H, CHCHN), 6.51 (d, J = 15.6 Hz, 1H, CHPh), 7.20-7.38 (m, 5H, 
ArH); 13C NMR δC: 28.2 [CO2C(CH3)3], 36.9 (CH2CCO2Me), 45.2 
(CH2CHCO2But), 51.2 (CCO2CH3), 52.6 (CHCO2But), 56.0 (CH2N), 66.9 
(CHN), 74.3 (CHOH), 75.7 (CCO2Me), 80.9 [CO2C(CH3)3], 126.7, 127.9, 
128.7, 136.6 (ArC), 127.7 (CHCHN), 134.9 (CHPh), 171.1 (CHCO2But), 
176.7 (CCO2Me); MS (EI-GC) m/z: 387 (M+, <1%), 369 (11), 329 (10), 310 
(15), 268 (30), 209 (100), 241 (11), 240 (17), 105 (12);Microanalysis 
calculated for C22H29NO5: C, 68.2; H, 7.5; N, 3.6%; found: C, 68.5; H, 7.3; 
N, 3.7%. 
2-tert-Butyl 7a-methyl (2R,3R,6R,7aR)-6-hydroxy-3-[(E)-styryl]hexahydro-
1H-pyrrolizine-2,7a-dicarboxylate 19c´:27 Sticky brown oil, 11 mg 
(8%); = +43.3  (c 1, CHCl3); IR (neat)  νmax 3002, 2955, 2315, 
1721, 1708 cm-1; 1H NMR δH: 1.30 [s, 1H, CO2C(CH3)3], 2.03 (dd, J = 13.9, 
6.1 Hz, 1H, CHHCCO2Me), 2.16 (dd, J = 13.4, 11.9 Hz, 1H, CHHCHCO2 
But), 2.49 (dd, J = 14.0, 2.0 Hz, 1H, CHHCCO2Me), 2.58 (dd, J = 13.4, 6.9 
Hz, 1H, CHHCHCO2But), 2.91 (dd, J = 11.7, 2.5 Hz, 1H, CHHN), 3.37 (dd, 
J = 11.7, 5.4 Hz, 1H, CHHN), 3.49 (dd, J = 11.9, 7.4 Hz, 1H, CHCO2But), 
3.78 (s, 3H, CCO2CH3), 4.11 (dd, J = 10.4, 7.4 Hz, 1H, CHN), 4.40 (m, 1H, 
CHOH), 5.88 (dd, J = 15.6, 10.4 Hz, 1H, CHCHN), 6.57 (d, J = 15.5 Hz, 
1H, CHPh), 7.26-7.37 (m, 5H, ArH); 13C NMR δC: 28.2 [CO2C(CH3)3], 36.8 
(CH2CCO2Me), 46.5 (CH2CHCO2But), 51.4 (CCO2CH3), 53.0 (CHCO2But), 
57.1 (CH2N), 66.6 (CHN), 75.2 (CHOH), 75.5 (CCO2Me), 81.1 
[CO2C(CH3)3], 125.7 (CHCHN), 126.7, 128.2, 128.8, 136.0 (ArC), 136.3 
(CHPh), 171.0 (CHCO2But), 176.5 (CCO2Me); MS (EI-GC) m/z: 387 (M+, 
<1%), 369 (10), 329 (10), 328 (11), 311 (15), 310 (13), 209 (100), 241 (13), 
240 (21), 105 (10); Microanalysis calculated for C22H29NO5: C, 68.2; H, 7.5; 
N, 3.6%; found: C, 68.6; H, 7.4; N, 3.5%. 
Methyl (1S,2S,3S,6R,7aR)-6-hydroxy-1-methyl-2-(2-oxooxazolidine-3-
carbonyl)-3-[(E)-styryl]hexahydro-1H-pyrrolizine-7a-carboxylate 19d: 
Yellow needles, 161 mg (78%), mp: 122-124 ºC; = -199.9  (c 1, 
CHCl3); IR (neat)  νmax 2948, 2923, 2874, 1776, 1725, 1690, 1387, 1213 
cm-1; 1H NMR δH: 0.96 (d, J = 6.8 Hz, 3H, CHCH3), 1.83 (br. s, 1H, OH), 
1.92 (dd, J = 13.7, 4.7 Hz, 1H, CHHC(CO2Me)], 2.77 [dd, J = 13.7, 6.0 Hz, 
1H, CHHC(CO2Me)], 2.98-3.16 (m, 3H, CH2N, CHCH3), 3.67 (ddd, J = 
10.9, 9.3, 6.6 Hz, 1H, CHHNCO), 3.76 (s, 3H, CO2CH3), 3.93 (ddd, J = 
10.9, 9.4, 7.0 Hz, 1H, CHHNCO), 4.12 (deform ddd, J = 9.4, 9.2, 7.0 Hz, 
1H, CHHOCO), 4.28 (deform ddd, J = 9.3, 9.2, 6.6 Hz, 1H, CHHOCO), 
4.44 (m, 1H, CHOH), 4.53 (dd, J = 11.4, 8.5 Hz, 1H, CHCON), 4.59 (dd, J 
= 10.2, 8.5 Hz, 1H, CHN), 6.27 (dd, J = 15.7, 10.2 Hz, 1H, CHCHN), 6.51 
(d, J = 15.7 Hz, 1H, CHPh), 7.20-7.36 (m, 5H, ArH); 13C NMR δC: 13.4 
(CHCH3), 42.8 (CH2CCO2Me), 43.0 (CH2N), 44.1 (CHCH3), 52.2 (CHCON), 
56.1 (CH2NCO), 56.3 (CO2CH3),  62.2 (CH2OCO), 64.7 (CHN), 73.5 
(CHOH), 79.3 (CCO2Me), 126.7, 128.1, 128.8, 136.5 (ArC), 128.1 
(CHCHN), 134.1 (CHPh), 153.0 (NCO2), 171.4 (CON), 175.4 (CCO2Me); 
MS (EI-GC) m/z: 414 (M+, <1%), 259 (16), 231 (10), 201 (15), 200 (100), 
182 (35), 172 (20), 156 (10), 115 (25); HRMS calculated for C22H26N2O6 
+1: 415.1869; found: 415.1852. 
Methyl (1R,2R,3R,6R,7aS)-6-hydroxy-1-methyl-2-(2-oxooxazolidine-3-
carbonyl)-3-[(E)-styryl]hexahydro-1H-pyrrolizine-7a-carboxylate 19d´: 
Yellow needles, 9 mg (4%),mp: 106-109 ºC; = +112.9  (c 1, CHCl3); 
IR (neat)  νmax 2949, 2921, 1776, 1728, 1688, 1387, 1217 cm-1; 1H NMR 
δH: 0.99 (d, J = 6.8 Hz, 3H, CHCH3), 2.00 (dd, J = 13.7, 5.3 Hz, 1H, 
CHHC(CO2Me)], 2.69-2.79 [m, 2H, CHCH3, CHHC(CO2Me)], 2.87 (ddd, J = 
11.0, 2.4, 1.0 Hz, 1H, CHHN), 3.25 (dd, J = 11.0, 4.5 Hz, 1H, CHHN), 3.72 
(ddd, J = 10.9, 9.3, 6.7 Hz, 1H, CHHNCO), 3.79 (s, 3H, CO2CH3), 3.94 
(ddd, J = 10.9, 9.4, 6.9 Hz, 1H, CHHNCO), 4.14 (deform ddd, J = 9.3, 9.1, 
6.9 Hz, 1H, CHHOCO), 4.30 (deform ddd, J = 9.4, 9.1, 6.7 Hz, 1H, 
CHHOCO), 4.44 (m, 1H, CHOH), 4.55 (dd, J = 11.2, 8.3 Hz, 1H, CHCON), 
4.63 (dd, J = 10.4, 8.3 Hz, 1H, CHN), 5.98 (dd, J = 15.5, 10.4 Hz, 1H, 
CHCHN), 6.56 (d, J = 15.5 Hz, 1H, CHPh), 7.22-7.37 (m, 5H, ArH), OH nd; 
13C NMR δC: 13.6 (CHCH3), 42.8 (CH2CCO2Me), 44.1 (CHCH3), 44.3 
(CH2N), 52.4 (CHCON), 56.5 (CH2NCO), 56.8 (CO2CH3), 62.2 (CH2OCO), 
64.1 (CHN), 74.2 (CHOH), 78.6 (CCO2Me), 126.7, 128.3, 128.9, 136.3 
(ArC), 126.8 (CHCHN), 135.2 (CHPh), 153.0 (NCO2), 171.5 (CON), 175.5 
(CCO2Me); MS (EI-GC) m/z: 414 (M+, <1%), 259 (18), 231 (11), 201 (11), 
200 (100), 183 (10), 182 (35), 172 (27), 115 (19); HRMS calculated for 
C22H26N2O6 +1: 415.1869; found: 415.1860. 
Methyl (3aS,4S,7R,8aR,8bR)-7-hydroxy-2-methyl-1,3-dioxo-4-[(E)-
styryl]decahydropyrrolo[3,4-a]pyrrolizine-8a-carboxylate 19e:27 Sticky 
yellow oil, 112 mg (61%); = +78.1  (c 1, CHCl3);  IR (neat)  νmax 
3005, 2980, 2305, 1714, 1710, 1698 cm-1; 1H NMR δH: 2.31-2.41 (m, 1H, 
CHHCCO2Me), 2.71-2.83 (m, 3H, CHHCCO2Me, CH2N), 2.97 (s, 3H, 
NCH3), 3.52 (deform. dd, J = 8.5, 8.1 Hz, 1H, CHCON), 3.85  (s, 3H, 
CO2CH3), 3.95 (d, J = 8.1 Hz, 1H, CHCCO2Me), 4.21 (deform. dd, J = 9.1, 
8.5 Hz, 1H, CHN), 4.36 (m, 1H, CHOH), 6.23 (dd, J = 15.6, 9.1 Hz, 1H, 
CHCHN), 6.76 (d, J = 15.6 Hz, 1H, CHPh), 7.26-7.40 (m, 5H, ArH); 13C 
NMR δC: 26.1 (NCH3), 37.3 (CH2CCO2Me), 52.3, 53.1, (2xCHCON), 54.4 
(CCO2CH3), 55.1 (CH2N), 65.7 (CHN), 75.3 (CHOH), 77.9 (CCO2CH3), 
125.3 (CHCHN), 126.9, 128.2, 128.7, 135.7 (ArC), 136.0 (CHPh),  176.2, 
176.3  (2xCON), 177.1 (CO2Me); MS (EI-GC) m/z: 370 (M+, <1%), 352 
(10), 312 (10), 293 (100), 243 (21), 210 (12), 182 (40), 115 (10); HRMS 
calculated for C20H22N2O5 +1: 371.1607; found: 371.1621. 
Endo-19e’ could not be separated. 
2-tert-Butyl 7a-methyl (2S,3R,6R,7aS)-6-hydroxy-3-phenylhexahydro-1H-
pyrrolizine-2,7a-dicarboxylate 20a: Colorless prisms, 98 mg (75%), mp: 
108-112 ºC; = -2.4  (c 1, CHCl3); IR (neat)  νmax 3196, 2977, 2954, 
2899, 1719, 1162 cm-1; 1H NMR δH: 1.26 [s, 9H, CO2C(CH3)3], 1.80 (m, 1H, 
OH), 1.84 (dd, J = 12.5, 8.5 Hz, 1H, CHHCHCO2But), 2.40-2.55 (m, 3H, 
CHHN, CHHCCO2Me, CHHCHCO2But), 2.71 (dd, J = 12.4, 6.4 Hz, 1H, 
CHHCCO2Me), 2.94 (dd, J = 9.5, 6.5 Hz, 1H, CHHN), 3.74 (s, 3H, 
CCO2CH3), 3.80 (ddd, J = 12.5, 9.0, 7.7 Hz, 1H, CHCO2But), 4.64 (d, J = 
9.0 Hz, 1H, CHN), 4.65 (deform. dddd, J = 6.5, 6.5, 4.6, 4.5 Hz, 1H, 
CHOH),  7.22-7.33 (m, 5H, ArH); 13C NMR δC: 27.5 [CO2C(CH3)3], 37.4 
(CH2CCO2Me), 44.7 (CH2CHCO2But), 52.5 (CCO2CH3), 55.7 (CHCO2But), 
54.3 (CH2N), 66.7 (CHN), 74.9 (CHOH), 77.2 (CCO2Me), 80.6 
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[CO2C(CH3)3], 128.0, 128.4, 129.8, 138.2 (ArC), 170.8 (CHCO2But), 
176.6 (CCO2Me); MS (EI-GC) m/z: 361 (M+, <1%), 303 (11), 302 (51), 247 
(17), 246 (100); HRMS calculated for C20H27NO5+1: 362.1967; found: 
369.1970. 
Methyl (1R,2R,3S,6R,7aS)-6-hydroxy-3-phenyl-1,2-
bis(phenylsulfonyl)hexahydro-1H-pyrrolizine-7a-carboxylate 20b: Yellow 
solid, 146 mg (54%), mp: 73-75 ºC; = +21.5  (c 1, CHCl3); IR (neat)  
νmax 2975, 1715, 1300, 1151 cm-1; 1H NMR δH: 2.08 (dd, J = 14.4, 0.5 Hz, 
1H, CHHN), 2.59 (dd, , J = 9.4, 2.4 Hz, 1H, CHHCCO2Me), 3.17 (dd, , J = 
9.4, 5.5 Hz, 1H, CHHCCO2Me), 2.08 (dd, J = 14.4, 6.6 Hz, 1H, CHHN), 
3.90 (s, 3H, CO2CH3), 4.27 (dd, J = 6.8, 4.2 Hz, 1H, CHSO2Ph),  4.53 (m, 
1H, CHOH), 4.62 (d, J = 6.8 Hz, 1H, CHSO2Ph), 4.86 (d, J = 4.2 Hz, 1H, 
CHPh), 7.11-7.98 (m, 15H, ArH); 13C NMR δC: 41.6 (CH2CCO2Me), 53.3 
(CO2CH3), 54.1 (CH2N), 62.9, 65.9 [2xCH(SO2Ph)], 73.4 (CHN), 73.8 
(CHOH), 77.5 (CCO2Me), 128.3 128.5, 129.0, 129.5, 129.6, 129.9, 134.1, 
134.5, 136.6, 137.2, 138.1, 140.3 (ArC), 136.0 (CHPh), 174.1 (CCO2Me); 
MS (EI-GC) m/z: 541 (M+, <1%), 251 (11), 250 (76), 184 (11), 141 (41), 
125 (100), 110 (10), 109 (47), 78 (10), 77 (80), 65 (21), 51 (22); HRMS 
calculated for C27H27NO7S2 +1: 542.1307; found: 542.1310. 
Methyl (2S,4R)-1-[2-(tert-butoxycarbonyl)propyl]-4-hydroxypyrrolidine-2-
carboxylate 21: Sticky yellow oil, 72 mg (84%); = +61.5  (c 1, 
CHCl3); IR (neat)  νmax 3192, 2971, 1718, 1689 cm-1; 1H NMR δH: 1.44 [s, 
9H, CO2C(CH3)3], 1.26 [s, 9H, CO2C(CH3)3], 2.04-2.10 (m, 1H, 
CHHCO2But), 2.20-2.26 (m, 1H, CHHCO2But), 2.43 (deform. dd, J = 7.6, 
7.4 Hz, 2H, CHCO2Me),  CH2(CHNCO2Me)], 2.57 [dd, J = 10.1, 3.3 Hz, 1H, 
CHH(NCH2OH)], 2.83 [deform. ddd, J = 12.4, 7.6, 7.4 Hz, 1H, 
CHH(NCH2)], 3.01 [deform. ddd, J = 12.4, 7.6, 7.5 Hz, 1H, CHH(NCH2)], 
3.38 [dd, J = 10.1, 5.5 Hz, 1H, CHH(NCH2OH)], 3.63 (deform. dd, J = 7.6, 
7.4 Hz, 1H, CHCO2Me), 3.72 (s, 3H, CO2CH3), 4.46 (deform. dddd, J = 6.5, 
6.5, 3.5, 3.3 Hz, 1H, CHOH); 13C NMR δC: 28.2 [CO2C(CH3)3], 34.8 
(CH2CO2But), 39.6 (CH2(CHNCO2Me), 49.2 (CH2N), 52.0 (CO2CH3), 61.0 
(CH2(NCH2OH), 63.8 (CHNCO2Me), 70.5 (CHOH), 80.7 [CO2C(CH3)3], 
171.7 (CO2But), 174.0 (CO2Me); MS (EI-GC) m/z: 259 (M+, <1%), 243 (10), 
242 (11), 200 (17), 158 (23), 144 (100); HRMS calculated for C12H21NO5 
+1: 260.1498; found: 260.1509. 
Methyl (3aR*,3bR*,3cR*,6aS*,7S*,9R*,9aS*)-2-methyl-1,3,4,6-tetraoxo-5,9-
diphenyl-7-[(E)-styryl]dodecahydro-3bH-dipyrrolo[3,4-a:3',4'-f]pyrrolizine-
3b-carboxylate endo-22a: Pale yellow oil, 27 mg (67%); IR (neat)  νmax 
1725-1700, 1300, 1151 cm-1; 1H NMR δH: 1.22 (dd, J = 6.5, 1.7 Hz), 2.77 
(s, 3H, NCH3), 3.47 (m, 1H, =CCHCH), 3.50 (dd, J = 10.4, 8.2 Hz, 
PhCHCH), 3.93 (s, 3H, CO2CH3), 4.24 (dd. J = 9.3, 9.3 Hz, 1H, NCHC=), 
4.30 (d, J = 8.2 Hz, 1H, CCHCONPh ), 4.47 (d, J = 10.4 Hz, 1H, 
CCHCONMe),  4.53 (d, J = 8.3 Hz, 1H, NCHPh), 5.16 (ddd, J = 14.9, 9.9, 
1.7 Hz, 1H, CH3CH=CH), 5.55 (ddd, J = 14.9, 6.5, 0.6 Hz, 1H, CH3CH=) 
7.15-7.25 (m, 5H, ArH), 7.31 (dd, J = 8.5, 1.3 Hz, 2H, ArH), 7.49 (d, J = 7.4 
Hz, 1H, ArH), 7.57 (dd, J = 7.5, 1.0 Hz, 2H, ArH)   13C NMR δC: 17.2 
(=CCH3), 24.9 (NCH3),  48.4 (MeNCCHCH), 49.9 (MeNCCHC), 50.3 
(CHCHCHC=), 52.4 (CHCHCHC=), 53.5 (CO2CH3) , 66.1 (NCHCH=), 66.7 
(NCHPh), 80.9 (NCCO2Me), 123.2, 125.6, 127.2, 128.1, 128.2, 129.1, 
129.6, 131.5, 133.6, 138.7 (ArC), 170.5, 173.5, 174.6, 174.9, 175.9 (4 x 
NC=O, CO2Me). MS (EI-GC) m/z: 575 (M+, <1%), 513(8), 455(25), 454(83), 
341(21), 340(100), 193(100), 282(14), 281(66); HRMS calculated for 
C34H29N3O6: 575.2159; found: 575.2155. 
Dimethyl (2S*,3S*,7aR*)-3-[(E)-styryl]hexahydro-1H-pyrrolizine-2,7a-
dicarboxylate 23aa:27 Pale orange needles, 132 mg (80%), mp: 107-110 
ºC; IR (neat)  νmax 2985, 2939, 2305, 1714, 1691 cm-1; 1H NMR δH: 1.72–
1.93 (m, 3H, CH2CH2N, CHHCCO2Me), 2.22 (deform. dd, J = 13.0, 12.8 
Hz, 1H, CHHCHCO2Me), 2.31 (deform. ddd, J = 8.6, 6.9 Hz, 1H, 
CHHCCO2Me), 2.64 (dd, J = 13.0, 6.7 Hz, 1H, CHHCHCO2Me), 2.89 
(deform. ddd, J = 11.2, 6.7, 2.3 Hz, 1H, CHHN), 3.10 (m, 1H, CHHN), 3.51-
3.58 (m, 4H, CHCO2Me, CHCO2CH3), 3.75 (s, 3H, CCO2CH3), 4.19 (dd, J 
= 10.4, 6.4 Hz, 1H, CHN), 5.98 (dd, J = 15.5, 10.4 Hz, 1H, CHCHN), 6.56 
(d, J = 15.5 Hz, 1H, CHPh), 7.28-7.35 (m, 5H, ArH); 13C NMR δC: 28.0 
(CH2CH2N), 36.5 (CH2CCO2Me), 37.2 (CH2CHCO2Me), 48.8 (CH2N), 50.0 
(CHCO2Me), 51.9 (CHCO2CH3), 52.6 (CCO2CH3), 67.4 (CHN), 76.4 
(CCO2Me), 125.7 (CHCHN), 126.7, 128.0, 128.7, 136.5 (ArC), 135.5 
(CHPh), 172.2 (CHCO2Me), 177.0 (CCO2Me); MS (EI-GC) m/z: 329 (M+, 
3%), 271 (19), 270 (100), 243 (13), 238 (21), 210 (17), 184 (40), 123 (10), 
115 (10); Microanalysis calculated for C19H23NO4: C, 69.3; H, 7.0; N, 4.3%; 
found: C, 69.5; H, 7.2; N, 4.5%. 
7a-Benzyl 2-methyl (2S*,3S*,7aR*)-3-[(E)-styryl]hexahydro-1H-pyrrolizine-
2,7a-dicarboxylate 23ba: Brown prisms, 188 mg, (93%), mp: 100-103 ºC; 
IR (neat)  νmax 2985, 2310, 1717 cm-1; 1H NMR δH: 1.72–1.81, 1.84-1.97 
(m, 3H, CH2CH2N, CHHCCO2Me), 2.24 (deform. dd, J = 13.3, 12.3 Hz, 1H, 
CHHCHCO2Me), 2.32 (deform. ddd, J = 11.9, 8.6, 2.0 Hz, 1H, 
CHHCCO2Me), 2.66 (dd, J = 13.3, 6.7 Hz, 1H, CHHCHCO2Me), 2.93 
(deform. ddd, J = 11.1, 6.8, 2.4 Hz, 1H, CHHN), 3.11 (deform. ddd, J = 8.8, 
6.8, 5.0 Hz, 1H, CHHN), 3.49-3.58 (m, 4H, CHCO2Me, CHCO2CH3), 4.22 
(dd, J = 10.4, 7.5 Hz, 1H, CHN), 5.18 (d, J = 12.4 Hz, 1H, CHHPh), 5.23 (d, 
J = 12.4 Hz, 1H, CHHPh), 5.99 (dd, J = 15.5, 10.4 Hz, 1H, CHCHN), 6.58 
(d, J = 15.5 Hz, 1H, CHPh), 7.22-7.39 (m, 10H, ArH); 13C NMR δC: 28.0 
(CH2CH2N), 36.4 (CH2CCO2Me), 37.2 (CH2CHCO2Me), 48.8 (CH2N), 50.0 
(CHCO2Me), 51.9 (CHCO2CH3), 66.9 (CH2Ph), 67.4 (CHN), 76.5 
(CCO2Me), 125.8 (CHCHN), 126.7, 127.1, 128.1, 128.3, 128.7, 128.8, 
136.2, 136.6 (ArC), 135.5 (CHPh), 172.2 (CHCO2Me), 176.1 (CCO2Bn); 
MS (EI-GC) m/z: 405 (M+, <1%), 185 (14), 184 (100), 156 (10); HRMS 
calculated for C25H27NO4 +1:406.2018; found: 406.2014. 
2-Allyl 7a-methyl (2S*,3S*,7aR*)-2-methyl-3-[(E)-styryl]hexahydro-1H-
pyrrolizine-2,7a-dicarboxylate 23ab:27 Brown-yellow solid, 151 mg (82%), 
mp: 90-95 ºC; IR (neat)  νmax 2983, 1720, 1699, 2310, 1270 cm-1; 1H NMR 
δH: 1.44 (s, 3H, CCH3), 1.69-2.02 (m, 3H, CH2CH2N, CHHCCO2Me), 2.15-
2.24 (m, 1H, CHHCCO2Me), 2.51 [d, J = 13.7 Hz, 1H, 
CHHC(CH3)CO2Allyl], 2.64 [d, J = 13.7 Hz, 1H, CHHC(CH3)CO2Allyl], 2.92-
3.01 (m, 1H, CHHN), 3.08-3.16 (m, 1H, CHHN), 3.77 (s, 3H, CCO2CH3), 
3.80 (d, J = 10.4, Hz, 1H, CHN), 4.43-4.45 (m, 2H, CO2CH2CHCH2), 5.07 
(ddd, J = 10.4, 2.6, 1.2 Hz, 1H, CO2CH2CHCHH), 5.19 (ddd, J = 17.2, 2.6, 
1.2 Hz, 1H, CO2CH2CHCHH), 5.75 (ddt, J = 17.2, 10.4, 5.9 Hz, 1H, 
CO2CH2CHCH2), 5.95 (dd, J = 15.6, 10.4 Hz, 1H, CHCHN), 6.53 (d, J = 
15.6 Hz, 1H, CHPh), 7.23-7.34 (m, 5H, ArH); 13C NMR δC: 23.5 (CCH3), 
27.5 (CH2CH2N), 39.2 (CH2CCO2Me), 43.9 [CH2C(CH3)CO2Allyl], 49.0 
(CH2N), 52.7 (CCO2CH3), 55.5 (CCO2CH3), 65.7  (CO2CH2CHCH2), 74.6 
(CHN), 77.4 [C(CH3)CO2Allyl], 118.6 (CO2CH2CHCH2), 126.1 (CHCHN), 
126.7, 127.9, 128.7, 136.6 (ArC), 132.1 (CO2CH2CHCH2), 135.4 (CHPh), 
174.4 (CO2Allyl), 178.0 (CO2Me); MS (EI-GC) m/z: 369 (M+, <1%), 310 
(33), 243 (34), 185 (15), 184 (100), 115 (11); Microanalysis calculated for 
C22H27NO4: C, 71.5; H, 7.4; N, 3.8%; found: C, 72.2; H, 7.1; N, 4.2%. 
Methyl (1S*,2S*,3S*,7aR*)-1-methyl-2-(2-oxooxazolidine-3-carbonyl)-3-
[(E)-styryl]hexahydro-1H-pyrrolizine-7a-carboxylate 23ac: Yellowish 
needles, 159 mg (80%), mp: 115-118 ºC; IR (neat)  νmax 2975, 2959, 2927, 
2912, 1775, 1716, 1688, 1388, 1265 cm-1; 1H NMR δH: 0.98 (d, J = 6.8 Hz, 
3H, CHCH3), 1.69-1.86 [m, 3H, CH2CH2N, CHHC(CO2Me)], 2.52 [deform 
ddd, J = 10.8, 6.9, 6.8 Hz, 1H, CHHC(CO2Me)], 2.72 (dq, J = 11.6, 6.8 Hz, 
1H, CHCH3), 2.80 (deform ddd, J = 11.9, 10.8, 6.0 Hz, 1H, CHHN), 3.08 
(deform ddd, J = 11.9, 10.6, 6.4 Hz, 1H, CHHN),  3.70 (ddd, J = 10.9, 9.3, 
6.6 Hz, 1H, CHHNCO), 3.77 (s, 3H, CO2CH3), 3.94 (ddd, J = 10.9, 9.4, 6.9 
Hz, 1H, CHHNCO), 4.14 (deform ddd, J = 9.4, 9.2, 6.6 Hz, 1H, CHHOCO), 
4.30 (deform ddd, J = 9.3, 9.2, 6.9 Hz, 1H, CHHOCO), 4.53 (dd, J = 11.6, 
8.3 Hz, 1H, CHCON), 4.59 (dd, J = 10.4, 8.3 Hz, 1H, CHN), 6.05 (dd, J = 
15.5, 10.4 Hz, 1H, CHCHN), 6.55 (d, J = 15.5 Hz, 1H, CHPh), 7.21-7.37 
(m, 5H, ArH); 13C NMR δC: 13.5 (CHCH3), 27.6 (CH2CH2N), 34.8 (CHCH3), 
42.6 (CH2CCO2Me), 43.5 (CH2N), 48.9 (CHCON), 52.1 (CO2CH3), 56.1 
(CH2NCO), 62.0 (CH2OCO), 64.9 (CHN), 80.0 (CCO2Me), 126.6, 127.2, 
128.7, 136.3 (ArC), 128.0 (CHCHN), 134.7 (CHPh), 152.8 (NCO2), 171.5 
(CON), 175.5 (CCO2Me); MS (EI-GC) m/z: 398 (M+, <1%), 243 (11), 185 
(15), 184 (100), 156 (16); HRMS calculated for C22H26N2O5 +1: 399.1920; 
found: 399.1934. 
Methyl (3aS*,4S*,8aR*,8bR*)-2-methyl-1,3-dioxo-4-[(E)-
styryl]decahydropyrrolo[3,4-a]pyrrolizine-8a-carboxylate endo-23ad:27 
Sticky brown oil, 122 mg (69%); IR (neat)  νmax 2360, 2341, 1699, 1265 cm-
1; 1H NMR δH: 1.73-1.85, 1.95-2.08 (m, 2H, CH2CH2N), 2.31-2.40, 2.46-
2.59 (m, 3H, CH2CCO2Me, CHHN), 2.97 (s, 3H, NCH3), 3.08 (m, 1H, 
CHHN), 3.46 (deform. dd, J = 8.1 Hz, 1H, CHCHN), 3.81  (s, 3H, CO2CH3), 
3.89 (d, J = 8.1 Hz, 1H, CHCCO2Me), 4.20 (dd, J = 9.0, 8.1 Hz, 1H, CHN), 
6.37 (dd, J = 15.6, 9.0 Hz, 1H, CHCHN), 6.76 (d, J = 15.6 Hz, 1H, CHPh), 
7.21-7.42 (m, 5H, ArH); 13C NMR δC: 25.0 (NCH3), 25.3 (CH2CH2N), 30.3 
(CH2CCO2Me), 48.3 (CH2N), 51.2 (CHCCO2Me), 52.3 (CHCHCCO2Me), 
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53.2 (CCO2CH3), 64.6 (CHN), 78.9 (CCO2CH3), 123.4 (CHCHN), 126.9, 
128.1, 128.6, 136.7 (ArC), 135.9 (CHPh), 174.1, 176.7  (2xCON), 177.1 
(CO2Me); MS (EI-GC) m/z: 354 (M+, <1%), 296 (25), 295 (100), 243 (30), 
242 (10), 241 (10), 228 (11), 184 (13), 115 (12), 91 (11); Microanalysis 
calculated for C20H22N2O4: C, 67.8; H, 6.3; N, 7.9%; found: C, 68.2; H, 6.3; 
N, 8.0%. 
Methyl (3aS*,4S*,8aR*,8bR*)-2-methyl-1,3-dioxo-4-[(E)-
styryl]decahydropyrrolo[3,4-a]pyrrolizine-8a-carboxylate exo-23ad:27 Sticky 
brown oil, 22 mg (12%); IR (neat)  νmax 2370, 2328, 1715 cm-1; 1H NMR δH: 
1.83-2.02 (m, 3H, CH2CH2N, CHHCCO2Me), 2.72-2.81(m, 1H, 
CHHCCO2Me), 2.98 (s, 3H, NCH3), 3.02-3.09 (m, 2H, CH2N), 3.40 (d, J = 
9.5 Hz, 1H, CHCCO2Me), 3.56 (dd, J = 9.5, 7.5 Hz, 1H, CHCHN),  3.71 (s, 
3H, CO2CH3), 4.42 (deform. dd, J = 7.5, 7.0 Hz, 1H, CHN), 6.32 (dd, J = 
15.9, 7.0 Hz, 1H, CHCHN), 6.85 (d, J = 15.9 Hz, 1H, CHPh), 7.22-7.42 (m, 
5H, ArH); 13C NMR δC: 25.0 (NCH3), 25.3 (CH2CH2N), 36.3 (CH2CCO2Me), 
49.3 (CH2N), 51.1 (CHCCO2Me), 52.7 (CHCHCCO2Me), 57.1 (CCO2CH3), 
67.3 (CHN), 78.8 (CCO2CH3), 125.3 (CHCHN), 126.7, 128.1, 128.6, 136.3 
(ArC), 134.9 (CHPh), 172.1, 176.1  (2xCON), 176.3 (CO2Me); MS (EI-GC) 
m/z: 354 (M+, <1%), 296 (31), 295 (100), 243 (28), 242 (11), 228 (15), 184 
(12), 183 (10), 115 (14); Microanalysis calculated for C20H22N2O4: C, 67.8; 
H, 6.3; N, 7.9%; found: C, 68.6; H, 6.5; N, 8.1%. 
Benzyl (3aS*,4S*,8aR*,8bR*)-2-methyl-1,3-dioxo-4-[(E)-
styryl]decahydropyrrolo[3,4-a]pyrrolizine-8a-carboxylate endo-23bd: Brown 
prisms, 149 mg, (60%), mp: 92-95 ºC;  IR (neat)  νmax 2924, 1770, 1694 
cm-1; 1H NMR δH: 1.80-1.85, 1.96-2.06 (m, 2H, CH2CH2N), 2.38 (ddd, J = 
13.8, 9.5, 4.3 Hz, 1H, CHHCCO2Me), 2.49 (ddd, J = 13.8, 8.9, 7.9 Hz, 1H, 
CHHCCO2Me), 2.59 (deform. ddd, J = 9.4, 7.9, 7.8 Hz, 1H, CHHN), 2.99 
(s, 3H, NCH3), 3.07 (ddd, J = 9.4, 8.0, 3.4 Hz, 1H, CHHN), 3.46 (deform. 
dd, J = 8.2, 8.1 Hz, 1H, CHCHN), 3.85 (d, J = 8.1 Hz, 1H, CHCCO2Me), 
4.20 (deform. dd, J = 9.3, 8.2 Hz, 1H, CHN), 5.23 (d, J = 12.2 Hz, 1H, 
CHHPh), 5.29 (d, J = 12.2 Hz, 1H, CHHPh), 6.36 (dd, J = 15.6, 9.3 Hz, 1H, 
CHCHN), 6.74 (d, J = 15.6 Hz, 1H, CHPh), 7.26-7.45 (m, 10H, ArH); 13C 
NMR δC: 25.2 (CH2CH2N), 25.3 (NCH3), 30.0 (CH2CCO2Me), 48.0 (CH2N), 
51.0 (CHCCO2Me), 52.5 (CHCHCCO2Me), 64.3 (CHN), 67.5 (CH2Ph), 78.8 
(CCO2CH3), 123.6 (CHCHN), 126.9, 128.1, 128.3, 128.6, 128.7, 128.8, 
135.7, 135.8 (ArC), 136.7 (CHPh), 173.2, 176.7  (2xCON), 177.0 (CO2Bn); 
MS (EI-GC) m/z: 430 (M+, <1%), 185 (15), 184 (100), 156 (11); HRMS 
calculated for C26H26N2O4 +1:430.1971; found: 430.1953. 
Benzyl (3aR*,4S*,8aR*,8bS*)-2-methyl-1,3-dioxo-4-[(E)-
styryl]decahydropyrrolo[3,4-a]pyrrolizine-8a-carboxylate exo-23bd: Yellow 
prisms, 19 mg (9%), mp: 85-87 ºC; IR (neat)  νmax 2934, 1699 cm-1; 1H 
NMR δH: 1.84-2.05 (m, 3H, CHHCCO2Me, CH2CH2N), 2.68 (s, 3H, NCH3), 
2.70-2.79 (m, 1H, CHHCCO2Me), 3.05-3.13 (m, 2H, CH2N), 3.40 (d, J = 9.5 
Hz, 1H, CHCCO2Me), 3.56 (dd, J = 9.5, 8.2 Hz, 1H, CHN), 4.44 (ddd, J = 
8.2, 6.8, 1.0 Hz, 1H, CHN), 5.12 (s, 2H, CH2Ph), 6.34 (dd, J = 15.9, 6.8 Hz, 
1H, CHCHN), 6.83 (d, J = 15.9 Hz, 1H, CHPh), 7.25-7.45 (m, 10H, ArH); 
13C NMR δC: 24.8 (NCH3), 25.6 (CH2CH2N), 36.7 (CH2CCO2Me), 49.7 
(CH2N), 51.1 (CHCCO2Me), 57.6 (CHCHCCO2Me), 67.5 (CHN), 67.8 
(CH2Ph), 78.6 (CCO2CH3), 125.5 (CHCHN), 126.8, 128.2, 128.6, 128.8, 
128.8, 128.9, 134.8, 135.2 (ArC), 136.5 (CHPh), 171.6, 176.0  (2xCON), 
176.3 (CO2Bn); MS (EI-GC) m/z: 430 (M+, <1%), 184 (45), 182 (12), 181 
(100), 91 (10); HRMS calculated for C26H26N2O4 +1:430.1971; found: 
430.1953. 
Trimethyl (1R*,2R*,3S*,7aR*)-3-[(E)-styryl]hexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate endo-23ae:27 Sticky yellow oil, 137 mg (71%); IR 
(neat)  νmax 2965, 2915, 2306, 1715, 1713, 1699 cm-1; 1H NMR δH: 1.76–
1.86 (m, 1H, CHHCH2N), 1.93–2.03 (m, 1H, CHHCH2N), 2.08–2.17 (m, 1H, 
CHHCCO2Me), 2.52–2.61 (m, 1H, CHHCCO2Me), 2.83 (deform. ddd, J = 
10.8, 6.6, 6.5 Hz, 1H, CHHN), 3.09 (deform. ddd, J = 10.8, 6.6, 6.5 Hz, 1H, 
CHHN), 3.42 (d, J = 11.7 Hz, 1H, CHCCO2Me), 3.58, 3.69 (s, 6H, 
2xCHCO2CH3), 3.70 (s, 3H, CCO2CH3), 4.02 (dd, J = 11.7, 8.2 Hz, 1H, 
CHCHN), 4.28 (dd, J = 10.4, 8.2 Hz, 1H, CHN), 5.96 (dd, J = 15.5, 10.4 Hz, 
1H, CHCHN), 6.56 (d, J = 15.5 Hz, 1H, CHPh), 7.25-7.35 (m, 5H, ArH); 13C 
NMR δC: 27.6 (CH2CH2N), 35.8 (CH2CCO2Me), 48.8 (CH2N), 52.1, 52.2 
(2xCHCO2Me), 52.4, 52.6, 53.6 (3xCO2CH3), 65.7 (CHN), 78.2 (CCO2Me), 
125.3 (CHCHN), 126.7, 128.2, 128.7, 136.3 (ArC), 135.8 (CHPh), 171.1, 
171.7 (2xCHCO2Me), 174.1 (CCO2Me); MS (EI-GC) m/z: 387 (M+, <1%), 
271 (19), 270 (100), 243 (13), 238 (21), 210 (17), 184 (40), 123 (10), 115 
(10); Microanalysis calculated for C21H25NO6: C, 65.1; H, 6.5; N, 3.6 %; 
found: C, 65.4; H, 7.0; N, 3.9%. 
Exo-25ae could not be separated. 
Methyl (1S*,2S*,3S*,7aR*)-2-nitro-1-phenyl-3-[(E)-styryl]hexahydro-1H-
pyrrolizine-7a- carboxylate endo-23af:27 Sticky brown oil, 132 mg (67%); IR 
(neat)  νmax 3003, 2983, 2872, 1726, 1536 cm-1; 1H NMR δH: 1.86–2.10 (m, 
3H, CH2CH2N, CHHCCO2Me), 2.68-2.76 (m, 1H, CHHCCO2Me), 2.92 (ddd, 
J = 10.1, 6.7, 4.5 Hz, 1H, CHHN), 3.25 (ddd, J = 10.1, 7.5, 6.3 Hz, 1H, 
CHHN), 3.37 (s, 3H, CCO2CH3), 4.17 (d, J = 11.3 Hz, 1H, CHCCO2Me), 
4.79 (dd, J = 10.2, 7.9 Hz, 1H, CHN), 6.10 (dd, J = 11.3, 7.8 Hz, 1H, 
CHNO2), 6.14 (dd, J = 15.5, 10.3 Hz, 1H, CHCHN), 6.72 (d, J = 15.5 Hz, 
1H, CHPh), 7.23-7.40 (m, 10H, ArH); 13C NMR δC: 27.4 (CH2CH2N), 35.5 
(CH2CCO2Me), 48.6 (CH2N), 52,1 (CCO2CH3), 55.4 (CHCCO2CH3), 66.2 
(CHN), 80.5 (CCO2Me), 91.9 (CHNO2), 122.7 (CHCHN), 127.1, 127.3, 
128.3, 128.6, 128.7, 128.9, 134.1, 135.8 (ArC), 138.3 (CHPh), 173.6 
(CCO2Me); MS (EI-GC) m/z: 392 (M+, <1%), 243 (11), 185 (14), 184 (100), 
156 (16); HRMS calculated for C23H24N2O4+1: 393.1814; found: 393.1800. 
Methyl (1R*,2S*,3S*,7aR*)-1-nitro-2-phenyl-3-[(E)-styryl]hexahydro-1H-
pyrrolizine-7a-carboxylate endo-24af:27 Sticky brown oil, 23 mg (12%); IR 
(neat)  νmax 3015, 2979, 2872, 1725, 1530 cm-1; 1H NMR δH: 1.57-1.63 (m, 
1H, CHHCH2N), 1.96-2.02 (m, 2H, CHHCH2N, CHHCCO2Me), 2.46-2.52 
(m, 1H, CHHCCO2Me), 3.03 (ddd, J = 10.8, 8.7, 6.1 Hz, 1H, CHHN), 3.13-
3.19 (m, 1H, CHHN), 4.06 (dd, J = 11.6, 10.2 Hz, 1H, CHPh), 4.23 (ddd, J 
= 11.6, 7.6, 0.5 Hz, 1H, CHN), 5.94 (d, J = 10.2 Hz, 1H, CHNO2), 6.18 (dd, 
J = 15.9, 7.6 Hz, 1H, CHCHN), 6.44 (dd, J = 15.9, 0.5 Hz, 1H, CHPh), 
7.24-7.40 (m, 10H, ArH); 13C NMR δC: 26.0 (CH2CH2N), 32.1 
(CH2CCO2Me), 50.7 (CH2N), 51.0 (CCO2CH3), 53.6 (CHPh), 67.8 (CHN), 
76.2 (CCO2Me), 97.1 (CHNO2), 123.8 (CHCHN), 126.6, 127.9, 128.0, 
128.2, 128.7, 129.2, 136.1, 136.2 (ArC), 136.4 (CHPh), 173.5 (CCO2Me); 
MS (EI-GC) m/z: 392 (M+, <1%), 243 (10), 185 (15), 184 (100), 156 (17), 
115 (10); HRMS calculated for C23H24N2O4+1: 393.1814; found: 393.1806. 
Methyl (2S*,3S*,7aR*)-2-(phenylsulfonyl)-3-[(E)-styryl]hexahydro-1H-
pyrrolizine-7a-carboxylate endo-23ag: Brown prisms, 146 mg (71%), mp: 
130-135 ºC; IR (neat)  νmax 2955, 2878, 1726, 1303, 1147 cm-1; 1H NMR 
δH: 1.74-1.93 (m, 3H, CH2CH2N, CHHCCO2Me), 2.34-2.48 (m, 2H, 
CHHCCO2Me, CHHN), 2.83-2.93 [m, 2H, CHHN, CHHCH(SO2Ph)], 3.07-
3.13 [m, 1H, CHHCH(SO2Ph)], 3.74 (s, 3H, CO2CH3), 3.95 (dd, J = 10.2, 
6.7 Hz, 1H, CHN), 4.20 [deform dt, J = 12.2, 6.7 Hz, 1H, CH(SO2Ph)CH], 
6.20 (dd, J = 15.6, 10.2 Hz, 1H, CHCHN), 6.30 (d, J = 15.6 Hz, 1H, CHPh), 
7.30-7.48 (m, 7H, ArH), 7.60-7.64 (m, 1H, ArH), 7.79-7.81 (m, 2H, ArH); 
13C NMR δC: 27.6 (CH2CH2N), 35.0 (CH2CCO2Me), 37.2 (CH2CCO2Me), 
48.1 (CH2N), 52.8 (CO2CH3), 66.2 (CHN), 67.6 [CH(SO2Ph)], 75.8 
(CCO2Me), 123.7 (CHCHN), 127.0, 128.2, 128.6, 128.8, 129.0,  133.8, 
136.4, 139.3 (ArC), 136.0 (CHPh), 176.0 (CCO2Me); MS (EI-GC) m/z: 411 
(M+, <1%), 239 (15), 238 (100), 210 (10), 96 (21), 77 (10); HRMS 
calculated for C23H25NO4S +1: 412.1582; found: 412.1589. 
Exo-23ag could not be separated. 
Methyl (1R*,2R*,3S*,7aS*)-1,2-bis(phenylsulfonyl)-3-[(E)-styryl]hexahydro-
1H-pyrrolizine-7a-carboxylatetricarboxylate endo-23ah:27 Sticky pale yellow 
oil, 183 mg (66%); IR (neat)  νmax 2991, 2934, 1708, 1310, 1141 cm-1; 1H 
NMR δH: 1.99–2.05 (m, 2H, CH2CH2N), 2.14-2.22 (m, 1H, CHHCCO2Me), 
3.03-3.07 (m, 1H, CHHCCO2Me), 3.14-3.21 (m, 1H, CHHN), 3.32-3.38 (m, 
1H, CHHN), 3.87 (s, 3H, CCO2CH3), 4.51 (d, J = 8.1 Hz, 1H, CHCCO2Me), 
4.71 (dd, J = 10.0, 8.2 Hz, 1H, CHN), 5.04 (deform. dd, J = 8.2, 8.1 Hz, 1H, 
CHN), 6.20 (d, J = 15.7 Hz, 1H, CHPh), 6.47 (dd, J = 15.7, 10.0 Hz, 1H, 
CHCHN), 7.13-8.04 (m, 15H, ArH); 13C NMR δC: 25.6 (CH2CH2N), 35.1 
(CH2CCO2Me), 49.1 (CH2N), 53.1 (CHCO2CH3), 65.7 (CHN), 73.7 
[CH(SO2Ph)CH], 74.5 [CH(SO2Ph)CCO2Me],  78.8 (CCO2Me), 122.7 
(CHCHN), 126.9, 128.3, 128.6, 128.9, 129.0,  129.6, 133.6, 133.9, 134.5, 
135.9, 139.2, 141.5 (ArC), 136.7 (CHPh), 170.9 (CCO2Me); MS (EI-GC) 
m/z: 493 (10), 492 (11), 410 (10), 310 (11), 244 (31), 243 (100), 128 (15), 
115 (17); HRMS calculated for C29H29NO6S2 +1: 552.1514; found: 
552.1548. 
Methyl (1S*,2S*,3S*,7aS*)-1,2-bis(phenylsulfonyl)-3-[(E)-styryl]hexahydro-
1H-pyrrolizine-7a-carboxylate exo-23ah:27 Sticky yellow oil, 28 mg (10%); 
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IR (neat)  νmax 2979, 2910, 1715, 1300, 1148 cm-1; 1H NMR δH: 2.02–
2.17 (m, 3H, CH2CH2N, CHHCCO2Me), 2.94-3.16 (m, 3H, CHHCCO2Me, 
CH2N), 3.83 (s, 3H, CCO2CH3), 4.03 (deform dd, J = 4.3, 4.1 Hz, 1H, 
CH(SO2Ph)CH), 4.38 (dd, J = 8.4, 4.3 Hz, 1H, CHN), 5.06 (d, J = 4.1 Hz, 
1H, CH(SO2Ph)CCO2Me), 6.13-6.24 (m, 2H, CHCHN, CHPh), 7.14-7.90 
(m, 15H, ArH); 13C NMR δC: 26.4 (CH2CH2N), 32.4 (CH2CCO2Me), 47.2 
(CH2N), 53.3 (CHCO2CH3), 64.7 (CHN), 66.9 [CH(SO2Ph)CH], 71.7 
[CH(SO2Ph)CCO2Me],  79.8 (CCO2Me), 125.9 (CHCHN), 126.7, 128.2, 
128.6, 128.9, 128.9,  129.3, 129.3, 134.2, 134.3, 135.7, 137.0, 138.5 (ArC), 
135.2 (CHPh), 173.9 (CCO2Me); MS (EI-GC) m/z: 551 (M+, <1%), 492 (15), 
410 (10), 311 (10), 310 (10), 244 (25), 243 (100), 128 (11), 115 (21); 
HRMS calculated for C29H29NO6S2 +1: 552.1514; found: 552.1565. 
Dimethyl (2S*,3S*,7aR*)-3-[(E)-prop-1-en-1-yl]hexahydro-1H-pyrrolizine-
2,7a-dicarboxylate endo-25aa:27 Sticky brown oil, 113 mg (85%); IR (neat)  
νmax 2985, 2939, 2305, 1714, 1691 cm-1; 1H NMR δH: 1.69 (d, J = 6.5 Hz, 
3H, CHCH3),  1.71–1.85 (m, 3H, CH2CH2N, CHHCCO2Me), 2.02-2.12 (m, 
1H, CHHCO2Me), 2.20-2.23 (m, 1H, CHHCHCO2Me), 2.55 (dd, J = 13.2, 
6.7 Hz, 1H, CHHCHCO2Me), 2.79-2.87 (m, 1H, CHHN), 3.02-3.07 (m, 1H, 
CHHN), 3.41 (deform. ddd, J = 12.7, 7.5, 6.7 Hz, 1H, CHCO2Me), 3.61 (s, 
3H, CHCO2CH3), 3.72 (s, 3H, CCO2CH3), 3.99 (dd, J = 10.3, 7.5 Hz, 1H, 
CHN), 5.25 (dd, J = 15.0, 10.3 Hz, 1H, CHCHN), 5.68 (dq, J = 15.0, 6.5 Hz, 
1H, CHMe); 13C NMR δC: 17.9 (CHCH3), 27.6 (CH2CH2N), 36.4 
(CH2CHCO2Me), 37.1 (CH2CCO2Me), 48.6 (CH2N), 49.8 (CHCO2Me), 51.7 
(CHCO2CH3), 52.6 (CCO2CH3), 67.3 (CHN), 76.3 (CCO2Me), 126.8 
(CHCHN), 132.1 (CHMe), 172.5 (CHCO2Me), 177.0 (CCO2Me); MS (EI-
GC) m/z: 267 (M+, <1%), 208 (100), 207 (10), 181 (25), 59 (10); 
Microanalysis calculated for C14H21NO4: C, 62.9; H, 7.9; N, 5.2%; found: C, 
63.3; H, 7.4; N, 5.4%. 
2-Allyl 7a-methyl (2S*,3S*,7aR*)-2-methyl-3-[(E)-prop-1-en-1-yl]hexahydro-
1H-pyrrolizine-2,7a-dicarboxylate endo-25ab: Pale yellow needles, 130 mg 
(85%), mp 107-108 ºC (hexanes/AcOEt); IR (neat)  νmax 2980, 2935, 2315, 
1715, 1690 cm-1; 1H NMR δH: 1.36 (s, 3H,CH3), 1.68 (dd, J = 1, and 6.5 Hz, 
3H, CHCH3),  1.71–2.00 (m, 3H, CH2CH2N, CHHCCO2Me), 2.15 (m, 1H, 
CHHCO2Me), 2.42, 2.53 (2d, J = 13.5 Hz, 2H, CH2CMeCO2Me), 2.90, 3.05 
(2m, 2H, CH2N), 3.52 (d, J = 10 Hz, 1H, CHN), 3.74 (s, 3H, CHCO2CH3), 
4.51 (d, J = 6 Hz, 2H, CH2O),  5.19-5.35 (m, 3H, CH=CH2), 5.64, 5.85 (2m, 
2H, HC=CH); 13C NMR δC: 8.9 (CHCH3), 27.5 (CH2CH2N), 30.9 (CCH3), 
35.7 (CH2CCO2Me), 45.7 (OCH3), 48.7 (CH2N),52.1 [CH2C(CH3)CO2Allyl], 
53.4(CHN),65.6  (CO2CH2CHCH2), 78.1 [C(CH3)CO2Allyl],125.6 
(CO2CH2CHCH2), 126.6 (CHCHN),128.8 (CHCHCHN), 135.7 (CHMe), 
136.2 (CO2CH2CHCH2), 171.5, 174.0 (2xCO).MS (EI-GC) m/z: 307 (M+, 
2%); Microanalysis calculated for C17H25NO4: C, 66.4; H, 8.2; N, 4.6%; 
found: C, 66.3; H, 7.9; N, 4.4%. 
Dimethyl (2S*,3R*,7aR*)-3-phenylhexahydro-1H-pyrrolizine-2,7a-
dicarboxylate endo-26aa:27 Sticky colorless oil, 103 mg (68%); IR (neat)  
νmax 2900, 1718, 1687 cm-1; 1H NMR δH: 1.81–2.00 (m, 3H, CH2CH2N, 
CHHCCO2Me), 2.34-2.43 (m, 2H, CHHCCO2Me, CHHCHCO2Me), 2.54-
2.61 (m, 1H, CHHCHCO2Me), 2.64-2.76 (m, 2H, CH2N), 3.23 (s, 3H, 
CHCO2CH3), 3.76 (s, 3H, CCO2CH3), 3.88 (ddd, J = 13.0, 8.8, 7.4 Hz, 1H, 
CHCO2Me), 4.73 (d, J = 8.8 Hz, 1H, CHN), 7.15-7.17, 7.25-7.28 (m, 5H, 
ArH); 13C NMR δC: 28.3 (CH2CH2N), 36.3 (CH2CHCO2Me), 36.7 
(CH2CCO2Me), 47.2 (CH2N), 51.4 (CHCO2Me), 52.7 (CHCO2CH3), 52.5 
(CCO2CH3), 67.3 (CHN), 76.1 (CCO2Me), 127.9, 128.2, 129.3, 138.0 (ArC), 
172.2 (CHCO2Me), 177.3 (CCO2Me); MS (EI-GC) m/z: 303 (M+, <1%), 245 
(11), 244 (100), 226 (21), 218 (10), 217 (17), 185 (26), 77 (15); HRMS 
calculated for C17H21NO4 +1: 304.1549; found: 304.1553. 
Dimethyl (3R*,7aR*)-3-phenylhexahydro-1H-pyrrolizine-1,7a-dicarboxylate 
27aa:27 Sticky colorless oil, 26 mg (16%); IR (neat)  νmax 2935, 2903, 1720, 
1705 cm-1; 1H NMR δH: 1.37–1.48 (m, 1H, CHHCCO2Me), 1.65-1.86 (m, 
2H, CH2CH2N), 2..18 (ddd, J = 12.1, 6.7, 4.1 Hz, 1H, CHHCHPh), 2.26-
2.34 (m, 1H, CHHCCO2Me), 2.41-2.55 (m, 3H, CHHCHPh, CH2N), 3.72 (s, 
3H, CHCO2CH3), 3.82 (s, 3H, CCO2CH3), 3.80 (dd, J = 12.1, 6.7 Hz, 1H, 
CHCO2Me), 4.49 (dd, J = 12.8, 4.0 Hz, 1H, CHN), 7.27-7.45 (m, 5H, ArH); 
13C NMR δC: 25.8 (CH2CH2N), 29.2 (CH2CHPh), 33.0 (CH2CCO2Me), 50.7 
(CH2N), 51.0 (CHCO2Me), 52.0 (CHCO2CH3), 52.9 (CCO2CH3), 64.8 
(CHN), 76.4 (CCO2Me), 127.7, 128.3, 128.9, 137.7 (ArC), 173.1 
(CHCO2Me), 175.5 (CCO2Me); MS (EI-GC) m/z: 303 (M+, <1%), 245 (10), 
244 (100), 243 (10), 227 (10), 226 (23), 217 (14), 185 (15), 77 (13); HRMS 
calculated for C17H21NO4 +1: 304.1549; found: 304.1592. 
Dimethyl (2S*,3S*,7aR*)-3-isobutylhexahydro-1H-pyrrolizine-2,7a-
dicarboxylate endo-28aa:27 Colorless oil, 90 mg (80%); IR (neat)  νmax 
2986, 2956, 2903, 1716, 1700 cm-1; 1H NMR δH: 0.93 [d, 6H, J = 6.0 Hz, 
CH(CH3)2], 1.35-1.41 [m, 2H, CHHCH2N, CH(CH3)2], 1.52-1.62 (m, 1H, 
CHHCH2N), 1.74-1.83, 1.87-1.94 (m, 2H, CH2CCO2Me), 2.22 (dd, J = 13.7, 
5.4 Hz, 1H, CHHCHCO2Me), 2.41 (ddd, J = 12.6, 8.4, 4.0 Hz, 1H, 
CHHCHCO2Me), 2.57 (dd, J = 13.7, 9.1 Hz, 1H, CHHCHCO2Me), 2.92-
3.15 (m, 3H, CHN, CHHN, CHCO2Me), 3.68 (s, 3H, CHCO2CH3), 3.73 (s, 
3H, CCO2CH3); 13C NMR δC: 22.9 [CH(CH3)2], 25.0 (CH2CH2N), 26.1 
[CH(CH3)2], 35.8 (CH2CHN) 37.8 (CH2CCO2Me), 39.7 (CH2CHCO2Me), 
47.4 (CH2N), 48.6 (CHCO2CH3), 51.5 (CCO2CH3), 52.9 (CHCO2Me),  62.9 
(CHN), 76.1 (CCO2Me), 176.2 (CHCO2Me), 176.3 (CCO2Me); MS (EI-GC) 
m/z: 283 (M+, <1%), 225 (15), 224 (100), 198 (14), 197 (35), 165 (21), 128 
(11), 127 (10); Microanalysis calculated for C15H25NO4: C, 63.6; H, 8.9; N, 
4.9%; found: C, 63.5; H, 8.4; N, 5.1%. 
Ethyl 1,7a-dimethyl (1S*,3R*,7aR*)-hexahydro-1H-pyrrolizine-1,3,7a-
tricarboxylate exo-29aa:27 Sticky yellow oil, 88 mg (59%); IR (neat)  νmax 
2991, 2910, 1714, 1711, 1699 cm-1; 1H NMR δH: 1.30 (t, J = 7.1 Hz, 3H, 
CO2CH2CH3), 1.41 (ddd, J = 12.7, 11.4, 7.6 Hz, 1H, CHHCCO2Me), 1.80-
1.90 (m, 2H, CH2N), 2.15 (ddd, J = 12.7, 7.0, 4.8 Hz, 1H, CHHCHCO2Et), 
2.32-2.47 (m, 2H, CHHCHCO2Et, CHHCCO2Me), 2.52-2.61 (m, 1H, 
CHHN), 3.11-3.16 (m, 1H, CHHN), 3.59 (dd, J = 12.2, 7.0 Hz, 1H, 
CHCO2Me), 3.69 (s, 3H, CHCO2CH3), 3.76 (s, 3H, CCO2CH3), 4.00 (dd, J 
= 12.2, 4.8 Hz, 1H, CHCO2Et), 4.24 (q, J = 7.1 Hz, 2H, CO2CH2CH3); 13C 
NMR δC: 14.3 (CO2CH2CH3), 26.0 (CH2CH2N), 28.8 (CH2CHCO2Et), 32.4 
(CH2CCO2Me), 50.3 (CHCO2Me), 51.4 (CO2CH2CH3), 52.1 (CHCO2CH3), 
52.9 (CCO2CH3), 61.3 (CH2N), 64.7 (CHN), 76.7 (CCO2Me), 169.9, 172.3, 
174.7 (2xCO2Me, CO2Et); MS (EI-GC) m/z: 299 (M+, <1%), 241 (14), 240 
(100), 226 (21), 212 (23), 166 (10), 108 (21); HRMS calculated for 
C23H24N2O4 +1:300.1447; found: 300.1451. 
1-Allyl 3-ethyl 7a-methyl (1S*,3R*,7aR*)-1-methylhexahydro-1H-pyrrolizine-
1,3,7a-tricarboxylate exo-29ab: Sticky yellow oil, 63 mg (37%); IR (neat)  
νmax 2992, 1721, 1703, 2312 cm-1; 1H NMR δH: 1.22-1.47 (m, 8H, 
CO2CH2CH3, CH2CH2N, CCH3), 1.55-1.68 (m, 1H, CHHCCO2Me), 1.87 
(dd, J = 13.0, 5.4 Hz, 1H, CHHCCO2Me), 2.48-2.58 (m, 1H, 
CHHC(CH3)CO2Allyl], 2.68-2.86 [m, 2H, CHHC(CH3)CO2Allyl, CHHN], 
3.11-3-17 (m, 1H, CHHN), 3.75 (s, 3H, CCO2CH3), 4.14-4.29 (m, 3H,  
CHN, CO2CH2CH3), 4.51-4.70 (m, 2H, CO2CH2CHCH2), 5.26 (ddd, J = 
10.5, 2.4, 1.3 Hz, 1H, CO2CH2CHCHH), 5.40 (ddd, J = 17.2, 2.4, 1.5 Hz, 
1H, CO2CH2CHCHH), 5.94 (deform. dddd, J = 17.2, 10.5, 5.8, 5.6 Hz, 1H, 
CO2CH2CHCH2); 13C NMR δC: 14.2 (CO2CH2CH3), 22.0 (CCH3), 25.5 
(CH2CH2N), 34.8 (CH2CCO2Me), 37.8 [CH2C(CH3)CO2Allyl], 50.3 (CH2N), 
52.1 (CCO2CH3), 54.2 [C(CH3)CO2Allyl], 61.0 (CO2CH2CH3), 63.1 (CHN), 
65.7 (CO2CH2CHCH2), 82.0 (CCO2CH3), 118.3 (CO2CH2CHCH2), 131.8 
(CO2CH2CHCH2), 170.8 (CO2Et), 173.8 (CO2Allyl), 174.0 (CO2Me); MS (EI-
GC) m/z: 339 (M+, <1%), 281 (18), 280 (100), 266 (16), 122 (26); HRMS 
calculated for C17H25NO6 +1: 340.1760; found: 340.1770. 
Endo-30aa could not be separated. 
2-Allyl 3-ethyl 7a-methyl (2S*,3R*,7aR*)-2-methylhexahydro-1H-pyrrolizine-
2,3,7a-tricarboxylate endo-30ab: Sticky yellow oil, 30 mg (18%); IR (neat)  
νmax 2996, 1715, 1698, 2317, 1291 cm-1; 1H NMR δH: 1.27 (t, J = 7.1 Hz, 
3H, CO2CH2CH3), 1.44 (s, 3H, CCH3), 1.80-2.17 (m, 4H, CH2CH2N, 
CH2CCO2Me), 2.52 [d, J = 13.2 Hz, 1H, CHHC(CH3)CO2Allyl], 2.81 [d, J = 
13.2 Hz, 1H, CHHC(CH3)CO2Allyl], 2.80-2.88 (m, 1H, CHHN), 3.18 (ddd, J 
= 10.6, 7.7, 4.3 Hz, 1H, CHHN), 3.74 (s, 3H, CCO2CH3), 3.89 (s, 1H, CHN), 
4.07-4.21 (m, 2H,  CO2CH2CH3), 4.47-4.63 (m, 2H, CO2CH2CHCH2), 5.23 
(ddd, J = 10.4, 2.5, 1.2 Hz, 1H, CO2CH2CHCHH), 5.31 (ddd, J = 17.2, 2.5, 
1.5 Hz, 1H, CO2CH2CHCHH), 5.87 (deform. dddd, J = 17.2, 10.4, 5.9, 5.8 
Hz, 1H, CO2CH2CHCH2); 13C NMR δC: 14.3 (CO2CH2CH3), 25.1 (CCH3), 
27.2 (CH2CH2N), 38.1 (CH2CCO2Me), 43.5 [CH2C(CH3)CO2Allyl], 49.4 
(CH2N), 52.6 (CCO2CH3), 55.8 [C(CH3)CO2Allyl], 60.8 (CO2CH2CH3), 65.7 
(CO2CH2CHCH2), 72.8 (CHN), 77.4 (CCO2CH3), 118.6 (CO2CH2CHCH2), 
131.9 (CO2CH2CHCH2), 173.1 (CO2Et), 174.5 (CO2Allyl), 177.8 (CO2Me); 
MS (EI-GC) m/z: 339 (M+, <1%), 281 (18), 280 (100), 266 (28), 122 (24); 
HRMS calculated for C17H25NO6 +1: 340.1745; found: 340.1760. 
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3-Ethyl 1,2,7a-trimethyl (1S*,2S*,3R*,7aR*)-hexahydro-1H-pyrrolizine-
1,2,3,7a-tetracarboxylate exo-29ac: colorless oil, 143 mg (80%); IR (neat)  
νmax 2965, 1755, 1735 cm-1; 1H NMR δH: 1.27 (t, J = 7.1 Hz, 3H, 
CO2CH2CH3), 2.00-2.15 (m, 3H, CH2CH2N, CHHCCO2Me), 2.52-2.60 (m, 
1H, CHHCCO2Me), 2.77 (ddd, J = 9.7, 5.7, 2.2 Hz, 1H, CHHN), 3.02 (ddd, 
J = 9.7, 5.5, 2.5 Hz, 1H, CHHN), 3.67, 3.68, 3.69 (3s, 9H, 
CCO2CH3,2xCHCO2CH3), 3.69 (d, J = 11.8 Hz, 1H, CHCO2Me), 4.15 (q, J 
= 7.1 Hz, 2H, CO2CH2CH3), 4.15 (dd, J = 11.8, 7.9 Hz, 1H, CHCO2Me), 
4.28 (d, J = 7.9 Hz, 1H, CHCO2Et); 13C NMR δC: 14.3 (CO2CH2CH3), 28.3 
(CH2CH2N), 35.3 (CH2CCO2Me), 48.9 (CO2CH2CH3), 50.0, 52.3 
(2xCHCO2Me), 52.3, 52.5, 53.2 (3xCO2CH3), 61.2 (CH2N), 65.5 (CHN), 
78.9 (CCO2Me), 170.1, 171.0, 171.5, 174.0 (3xCO2Me, CO2Et); MS (EI-
GC) m/z: 357 (M+, <1%), 299 (17), 298 (100), 284 (17), 266 (62), 252 (17), 
238 (49), 224 (16), 206 (12), 192 (41), 166 (47), 134 (43), 107 (10), 106 
(17); HRMS calculated for C16H23NO8 +1:358.1502; found: 358.1485. 
3-Ethyl 1,2,7a-trimethyl (1R*,2R*,3R*,7aR*)-hexahydro-1H-pyrrolizine-
1,2,3,7a-tetracarboxylate endo-29ac: colorless oil, 143 mg (80%); IR (neat)  
νmax 2960, 1751, 1733 cm-1; 1H NMR δH: 1.30 (t, J = 7.1 Hz, 3H, 
CO2CH2CH3), 1.48 (ddd, J = 12.9, 11.0, 7.9 Hz, 1H, CHHCCO2Me), 1.81-
1.89 (m, 2H, CH2CH2N), 2.45-2.49 (m, 1H, CHHCCO2Me), 2.59-2.66 (m, 
1H, CHHN), 3.07-3-14 (m, 1H, CHHN), 3.64-3.71 (m, 1H, CHCO2CH3), 
3.72, 3.73, 3.80 (3s, 9H, CCO2CH3, 2xCHCO2CH3), 3.91 (d, J = 11.4 Hz, 
1H, CHCO2Me), 4.23-4.28 (m, 3H, CHN, CO2CH2CH3); 13C NMR δC: 14.2 
(CO2CH2CH3), 25.6 (CH2CH2N), 32.7 (CH2CCO2Me), 46.6, 52.4 
(2xCHCO2Me), 51.7 (CO2CH2CH3), 52.6, 53.2, 54.5 (3xCO2CH3), 61.7 
(CH2N), 65.6 (CHN), 76.6 (CCO2Me), 168.6, 171.1, 172.0, 173.9 
(3xCO2Me, CO2Et); MS (EI-GC) m/z: 357 (M+, <1%), 299 (17), 298 (100), 
284 (12), 267 (10), 266 (64), 252 (10), 238 (25), 192 (25), 166 (37), 134 
(34), 106 (12); HRMS calculated for C16H23NO8 +1:358.1502; found: 
358.1491. 
Ethyl (5R,5aR,8aS,8bS)-7-methyl-6,8-dioxo-5-[(E)-styryl]hexahydro-3H-
pyrrolo[3',4':3,4]pyrrolo[1,2-c]thiazole-8b(1H)-carboxylate  endo-31: 
colorless oil, 102 mg (63%); IR (neat)  νmax 2960, 1759, 1733 cm-1; 1H 
NMR δH: 3.01 (s, 3H, NCH3), 3.12 (d, 1H, J = 11.0 Hz, CCH2), 3.44 (d, J = 
11Hz, CCH2), 3.55-3.65 (d, J = 8.4 Hz 1H, CCH ) 3.67-3.70 (m, 1H, 
NCHCH), 3.84 (s, 3H, CO2CH3),  3.93 (d, 1H, J = 7.2 Hz, NCH2S), 3.97 (d, 
1H, J = 7.2 Hz, NCH2S),  4.40 (dd, J = 8.6, 0.8 Hz, 1H, NCH), 5.95 (dd, J = 
15.5, 9.7 Hz, 1H, CHCH=), 6.72 (d, J = 15.5 Hz, 1H, =CHPh)7.19-7.47 (m, 
5ArH); 13C NMR δC: 25.2 (NCH3), 35.2 (SCH2C), 48.1 (CCHC), 48.9 
(NCHCH), 52.4 (CO2CH3), 53.0 (SCH2N), 63.2 (NCH), 79.5 (NC), 124.0, 
126.9, 128.2, 128.6, 128.7, 135.9, 136.0 (ArC), 171.9 (CO2), 174.6 (CO), 
174.9(CO), MS (EI-GC) m/z: 372 (M+, 7%), 325(11), 314(20), 313(100), 
281(20), 115(18), 91(11); HRMS calculated for C19H20N2O4S: 372.1144; 
found: 372.1153. 
Exo-31could was lost during the separation. 
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